High-throughput screening to identify human microRNAs enhancing CRISPR/Cas9-based homologous recombination for cardiac gene correction by Schneider, Edoardo








High-throughput screening to identify 
human microRNAs enhancing 
CRISPR/Cas9-based homologous 




















Joint PhD Programme in Molecular Biology (JuMBO) 
 
“High-throughput screening to identify 
human microRNAs enhancing 
CRISPR/Cas9-based homologous 
recombination for cardiac gene 
correction” 
 















LIST OF FIGURES ................................................................................................................. 5 
LIST OF TABLES ................................................................................................................... 6 
ABSTRACT ............................................................................................................................. 7 
1. INTRODUCTION ............................................................................................................ 10 
1.1 Genome editing and engineering through gene therapy ..................................... 10 
1.1.1. How cells repair DNA damages ......................................................................................... 10 
1.1.1.1 Non-homologous end joining (NHEJ)........................................................................................ 10 
1.1.1.2 Single-strand DNA annealing (SSA) ........................................................................................... 11 
1.1.1.3 Homologous recombination (HR) .............................................................................................. 12 
1.1.2 Programmable nucleases as tool for precise gene modifications ........................ 15 
1.1.2.1 Zinc-finger endonucleases (ZFNs) .............................................................................................. 16 
1.1.2.2 Transcriptional activator-like effector nuclease (TALEN) endonucleases .............. 17 
1.1.2.3 Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 
endonuclease ...................................................................................................................................................... 18 
1.1.2.3.1 History of CRISPR/Cas9 discovery ................................................................................... 18 
1.1.2.3.2 Natural mechanism of action .............................................................................................. 20 
1.1.2.3.3 Diversity between Cas9 orthologs .................................................................................... 22 
1.1.2.3.4 Adaptation of Cas9 system to perform genome editing in eukaryotic cells ... 23 
1.1.2.3.5 CRISPR/Cas9 system engineering .................................................................................... 24 
1.1.2.4  Genome editing using CRISPR/Cas9 ........................................................................................ 28 
1.1.2.4.1 Ex-vivo Biomedical application of CRISPR/Cas9 system ....................................... 28 
1.1.2.4.2 In-vivo biomedical applications ......................................................................................... 30 
1.2 Adeno-Associated virus (AAV)....................................................................................... 34 
1.2.1 Biology of the wild type Adeno-Associated Virus ....................................................... 37 
1.2.2 Generation of recombinant AAV (rAAV) ........................................................................ 38 
1.2.3 Natural and synthetic serotypes ........................................................................................ 39 
1.2.4 Intracellular processing ......................................................................................................... 41 
1.2.5 AAV production ......................................................................................................................... 44 
1.2.6 Limitation in the use of AAV ................................................................................................ 45 
1.2.6.1 immune response against AAV treatment .............................................................................. 45 
1.2.6.2 Limitation in AAV tropism and transduction ........................................................................ 46 
1.2.6.3 Limited transgene packaging capacity ..................................................................................... 46 
1.3 MicroRNA .............................................................................................................................. 47 
1.3.1 MicroRNAs discovery ............................................................................................................. 47 




1.3.3 Mechanism of action of microRNAs .................................................................................. 49 
1.3.4 Modulation of endogenous microRNAs levels .......................................................................... 50 
1.3.5 MicroRNAs target identification ..................................................................................................... 51 
1.4 Human genetic cardiovascular disorders, the clinical demand ........................ 53 
1.4.1 Hypertrophic cardiomyopathy ........................................................................................... 55 
1.4.2 Dilated cardiomyopathy ........................................................................................................ 56 
1.4.3 Arrhythmogenic right ventricular cardiomyopathy (ARVC) ................................. 57 
1.4.4 Perspectives of gene correction for the treatment of inherited 
cardiomyopathies ............................................................................................................................... 57 
2. MATERIALS AND METHODS ..................................................................................... 59 
2.1 Cells ......................................................................................................................................... 59 
2.2 MicroRNA mimics and siRNAs ....................................................................................... 60 
2.3 MicroRNAs/siRNAs transfection ................................................................................... 60 
2.4 Production, purification and characterization of rAAV vectors ........................ 61 
2.5 The high-throughput screening .................................................................................... 61 
2.6 AAV transduction in HL-1 and cardiomyocytes....................................................... 62 
2.7 Fluorescence Microscopy, image acquisition and analysis ................................. 62 
2.8 Total RNA extraction from 6-well plates ................................................................... 63 
2.9 Reverse Transcription PCR ............................................................................................. 64 
2.10 Real-Time PCR .................................................................................................................. 65 
2.11 Total RNA extraction from Heart sections .............................................................. 66 
2.12 miRCURY miRNAs quantification ............................................................................... 66 
2.13 Cell cycle profile evaluation ......................................................................................... 67 
2.14 Western-Blot quantification ........................................................................................ 67 
2.15 Deep-sequencing analysis ............................................................................................ 69 
2.16 T7 endonuclease Assay .................................................................................................. 70 
2.17 3’UTR-Luciferase Assay ................................................................................................. 71 
2.18 Mouse cardiomyocyte preparation ........................................................................... 71 
2.19 Mice injection, hearts extraction and slices preparation .................................. 72 
3. RESULTS .......................................................................................................................... 73 
3.1 High content screening to identify human microRNAs affecting CRISPR-
Cas9-based homologous recombination ........................................................................... 73 
3.2 High-throughput screening protocol and image processing .............................. 76 
3.3 The identification of human microRNAs able to positively modulate 




3.4 Evaluation of the effect of the selected miRNAs on the modulation of the non 
homologous end joining DNA repair pathway ................................................................ 81 
3.5 The selected microRNAs modify the cell cycle profile .......................................... 83 
3.6 The selected molecules do not induce DNA damage and upregulate key 
components of homologous recombination machinery.............................................. 86 
3.7 Analysis of the transcriptome in cells transfected with hsa-miR-520c-3p, 
hsa-miR-302d-3p and has-miR-4469 ................................................................................. 88 
3.8 MAPK11 (p38β), a possible hsa-miR-4469 target .................................................. 90 
3.9 Evaluation of homologous recombination modulation by specific MAPK11 
inhibition ...................................................................................................................................... 92 
3.10 A strategy to investigate homologous recombination and the effect of the 
selected microRNAs in mouse CMs in vitro ...................................................................... 93 
3.11 In vivo evaluation of the effect of the selected microRNAs on Cas9-based 
homologous recombination................................................................................................... 96 
4. DISCUSSION .................................................................................................................... 98 
4.1 A high-content robotized screening identified novel factors to improve 
CRISPR/Cas9-mediated homologous recombination ................................................... 99 
4.2 The effect of the selected miRNAs was HR-specific, without affecting NHEJ
 ....................................................................................................................................................... 101 
4.3 Effect of the selected miRNAs on cell proliferation ............................................. 101 
4.4 Effect of the selected miRNAs and the DNA damage response ........................ 103 
4.5 Mechanism of action of hsa-miR-4469 .................................................................... 104 
4.6 Gene editing in cardiomyocytes ................................................................................. 105 
4.7 Gene editing in the heart .............................................................................................. 106 
4.8 Conclusions and future perspectives ....................................................................... 108 





LIST OF FIGURES 
 
Figure 1 Non-Homologous End Joining pathway (NHEJ) 
Figure 2 Single Strand DNA Annealing pathway (SSA) 
Figure 3 Homologous Recombination pathway (HR) 
Figure 4 Zinc-finger endonucleases (ZFNs) 
Figure 5 Transcriptional activator-like effector nuclease (TALEN) endonucleases 
Figure 6 Clustered regularly interspaced short palindromic repeats 
(CRISPR)/Cas9 endonuclease 
Figure 7 Intracellular AAV processing 
Figure 8 Human microRNAs biogenesis 
Figure 9 Schematic representation of the most frequent genetically determined 
cardiomyopathies 
Figure 10 HR detection assay  
Figure 11 The high-throughput screening workflow 
Figure 12 Results of the screening  
Figure 13 MicroRNA hits confirmation  
Figure 14 Effect of the selected miRNAs on NHEJ  
Figure 15 Cell cycle evaluation  
Figure 16 The selected molecules do not induce DNA damage and upregulate 
key components of HR machinery 
Figure 17 Transcriptome analysis of U2OS cells treated with the selected 
miRNAs  
Figure 18 MAPK11, a possible hsa-miR-4469 target 
Figure 19 The chemical inhibition of MAPK11 influence HR frequency  
Figure 20 Evaluation of the effect of the selected miRNAs at improving HR 
efficiency in vitro in mouse CMs 
Figure 21 Evaluation of the effect of the selected miRNAs at improving HR 





LIST OF TABLES 
 
Table 1 List of recombinant AAV used in the project  
Table 2 List of TaqMan probes  
Table 3 List of housekeeping genes used in Real Time PCR quantifications 
Table 4 List of EXIQON probes used to quantify the miRNAs 
Table 5 List of antibodies used in the project for Western-Blot quantifications 







The definitive treatment of genetic diseases through precise gene editing has 
been a long sought goal of gene therapy, yet hitherto unachieved at the clinical 
level. The CRISPR/Cas9-based technology ensures simple and efficient 
modification of the cellular genome and thus promises to change the 
perspective of treatment of hereditary disorders, including genetic 
cardiomyopathies. However, in mammals, gene correction through the 
homologous recombination (HR) machinery is largely less efficient than 
gene inactivation through the error prone, non-homologous end 
joining (NHEJ) route. This is particularly true in adult post-mitotic 
tissues, such as the heart, since HR commonly relies on S to G2/M-
phase transition. 
The main goal of this project is to identify genetic treatments able to 
enhance frequency of CRISPR/Cas9-induced HR in vitro and in the 
heart. By robotic high-throughput, high-content microscopy we 
systematically screened a library of 2,024 human microRNAs to search 
for regulators of HR-mediated gene correction. We identified 20 
miRNAs that significantly increase CRISPR/Cas9-induced HR events 
compared to controls (P<0.001). Interestingly, 10 among the top 
identified miRNAs belong to only two associated miRNAs families 
sharing the same seed sequence. A common and distinctive feature of 




pathway, including MRE11, NBN, RAD50 and RAD51. Another highly 
effective miRNA, not belonging to either of these two families, 
regulates expression of p38 beta, suggesting involvement of this MAPK 
in the HR process. 
To study the effect of these miRNAs in the cardiac context, we first 
designed a CRISPR-AAV-based HR detection tool allowing precise, in 
frame insertion of a promoterless GFP gene into the last exon of the 
Myosin regulating light chain 2 (Myl2) gene in Cas9-expressing 
cardiomyocytes. The selected miRNAs also markedly enhanced Cas9-
induced HR in this model. The same approach was then tested in vivo 
by producing AAV9 particles coding for the HR reporter system and the 
miRNAs and systemically injecting them in newborn Cas9+ mice. Also 
in this setting, the selected miRNAs increased the HR frequency up to 
4-folds over control.       
Together, these results are encouraging in indicating that transient 
cardiac treatment with miRNAs enhancing HR together with the use of 
pro-recombinogenic AAVs might be sufficient to increase gene 















1.1 Genome editing and engineering through gene therapy 
1.1.1. How cells repair DNA damages 
1.1.1.1 Non-homologous end joining (NHEJ) 
The non-homologous end joining (NHEJ) pathway, as defined for the first time 
in 1993 by Moore and coworkers (Moore and Haber 1996), corresponds to the 
imprecise correction of a diverse range of DNA substrates at double-strand 
breaks (DSBs). This correction mechanism resembles the classical pathway by 
which the cells repair DNA damages using a three-step process, which involves a 
nuclease, a polymerase and a ligase. Upon DSBs formation, the Ku proteins 
recognize and bind the two DNA strands (Mimori and Hardin 1986). These 
proteins form a heterodimer (Ku70 and Ku80), which protects the DNA ends 
from degradation and promotes the recruitment of the DNA-dependent protein 
kinase catalytic subunit (DNA-PKcs), having serine-threonine kinase activity, 
and Artemis. This complex recognizes and cleaves different types of DNA 
damaged overhangs. Artemis:DNA.PKcs presents 5’-endonucleolitic activity 
that produces nicks inside the 5’ overhang in order to create blunt DNA ends 
(Ma, Pannicke et al. 2002). Therefore, Artemis modifies the cleaved DNA 
overhangs to create substrates for the enzymatic ligation with the Ligase 4 
complex (Yannone, Khan et al. 2008), which has the ability to bind a variety of 
DNA ends (Gu, Lu et al. 2007). Once this occurs, through their BRCT domains, 
the error-prone polymerases mu and lambda (pol x), can bind the Ku:DNA 
complex and synthesize the new DNA sequences by adding rNTPs or dNTPs to 
the resected strands (Ma, Lu et al. 2004). Finally, the Ligase 4 complex catalyzes 
the last step of the DSB resolution, which corresponds to the rejoining of the 
DNA ends. In summary, the NHEJ pathway consists of a very conserved DNA 
repair pathway, the components of which share an extensive tolerance in the 
configuration of the DNA recognized targets. Consequently, this DNA repair 





1.1.1.2 Single-strand DNA annealing (SSA)  
Another mechanism by which cells repair DNA insults consists of the SSA 
pathway, which uses homologous repeats to solve the DSBs. The activation of 
this pathway involves the annealing of specific repeats flanking the DSBs, which 
produces deletions. One of the first evidences proposing SSA as a specific mode 
for DNA repair comes from the work of Sternberg and colleagues (Lin, Sperle et 
al. 1984). In their model, DSBs occur between homologous repeats and generate 
3’ ssDNA, which are then annealed to create an intermediate. It has been shown 
that the generation of these 3’ ssDNA sequences at the DSB locus corresponds 
to a key step for SSA activation. According to this information, it was 
demonstrated that this pathway requires a DNA end resection factor called CtIP 
(Bennardo, Cheng et al. 2008). The DNA repair process then requires a ligation 
step and a subsequent endonucleolytic cleavage of the non-homologous 3’ 
ssDNA sequences, which are mediated by RAD52 (Symington 2002) and by the 
Figure 1: The NHEJ pathway is a very conserved DNA repair pathway, the 
components of whcih share an extensive tolerance in the configuration of the 





ERCC1/XPF complex (Motycka, Bessho et al. 2004). Eventually, the activation of 
a polymerase results critical to fill the gaps. 
 
1.1.1.3 Homologous recombination (HR) 
Homologous recombination has always been the gold standard for gene therapy 
applications. Nevertheless, this is a very inefficient DNA repair mechanism in 
higher eukaryotes, which rarely occurs in dividing cells and is almost shutoff in 
differentiated and post-mitotic cells. Accordingly, it is known that many crucial 
components of the HR pathway are transcriptionally regulated depending on 
the different cell cycle phases (Cho, Campbell et al. 1998). During meiosis, HR 
drives many crucial biological processes such as prevention of the collapsing of 
damaged DNA replication forks (Michel, Grompone et al. 2004), chromosome 
segregation during the first meiotic division and telomere maintenance 
(McEachern and Haber 2006). Most relevant, the main role of HR during mitosis 
is to repair both spontaneous and induced DSBs with the substitution of 
damaged DNA with a similar or identical template sequence. The first evidence 
Figure 2: Model of Single Strand Anealling: The annealing of specific repeats 
The DNA repair process requires a ligation step and a subsequent 
endonucleolytic cleavage of the non-homologous 3’ ssDNA sequences, which 
are mediated by RAD52 (Symington 2002) and by the ERCC1/XPF 





of how this pathway works came from the study of Orr-Weaver and colleagues, 
who demonstrated how a non replicating plasmid, presenting a DSB and, within 
the same region, sequences with homology for the yeast genome, was able to 
efficiently recombine upon transformation (Orr-Weaver, Szostak et al. 1981). 
According to this study, the 3’ ssDNA tail of the DSB end invades the 
homologous duplex in the corresponding yeast genomic site and is then 
extended by DNA synthesis. The 3’ ssDNA invasion of the homologous duplex 
creates a displacement loop (D-loop), which induces binding of the tail with the 
sequence on the complementary side of the template DNA duplex by Watson-
Crick interactions. On the other hand, the non-invading 3’ ssDNA strand is then 
completed by DNA synthesis. Consequently, this forms a double-Holliday-
junction (dHJ) intermediate (Holliday 2007), which will generate, by random 
resolution, an identical number of crossover and noncrossover products. During 
meiosis, the production of crossover products corresponds to the asymmetric 
resolution of this intermediate, thus leading to the formation of new allelic 
combinations (Maloisel, Bhargava et al. 2004). This DNA correction model was 
defined as DSB repair (DSBR) (Szostak, Orr-Weaver et al. 1983) and corresponds 
to the canonical way by which cells repair DNA damages during meiosis. Indeed, 
it has been shown that DSBR pathway activation frequently occurs in hotspots 
for meiotic recombination, where DSBs can be generated (Kolodkin, Klar et al. 
1986). Nevertheless, this system does not represent the only mechanism by 
which HR can repair DSBs. Another possible sub-pathway, defined as synthesis-
dependent strand annealing (SDSA) (Ferguson and Holloman 1996), was 
proposed in 1996. Different from DSBR, SDSA corresponds to a conservative 
replication process, leading to the formation of non-crossover products, by 
which only one of the 3’ssDNA tail invades the homologous duplex, without the 
generation of the dHJ (Miura, Yamana et al. 2012). Upon strand invasion, a 
polymerase synthetizes the new DNA in the 5’ to 3’ direction. This step therefore 
creates a single HJ, which then dissociates from the DNA duplex allowing 
binding of the amplified displaced sequence to the other 3’ ssDNA on the other 




on the cleavage site, DNA synthesis fills the gaps and completes the repair 
process.  
It is possible to classify the key components of HR pathways into two main 
groups: proteins associated with the DNA damage response (DDR) that work as 
a complex composed by MRE11, RAD50 and NBS1 (MRN complex) and proteins  
 
specifically associated with HR (RAD51, RAD52, RAD54, RAD55, RAD57, RAD59, 
RDH54/TID1). As a first step, after DSBs formation, the MRN complex 
recognizes the damage and associates with the CtIP protein, enzyme that 
catalyzes the 5’-3’ end resection in order to generate the 3’ ssDNA tails (Davies, 
Forment et al. 2015). 
Another key protein directly associated with the initialization of the HR process 
is replication protein A (Ward, Norat et al.). This protein is a heterotrimeric DNA-
Figure 3: After the generation of a double strand break, cells can repair the 
damage through the HR pathway if a template DNA is present inside the cell. 
Two different sub-pathways (DSBR or SDSA) trigger the HR-mediated DSB 
resolution; they share the initial phases of cleavage recognition and 
stabilization, but differ in the consequent repair step. Depending on the 
specific process, HR-mediated DNA repair can generate crossover or non-





binding protein that recognizes and binds ssDNA sequences at the DSBs loci, 
prevents ssDNA degradation by cellular nucleases (Chen and Wold 2014) and 
promotes generation of 3’ ssDNA tails (Yan, Toczylowski et al. 2011). After DSBs 
formation, RPA is rapidly replaced, through the activity of RAD52, with the most 
important component of the pathway, the ATP-dependent recombinase RAD51. 
This protein exists as a ring composed by 7 monomers that binds the ssDNA and 
possesses motives able to hydrolyze ATP. After the first nucleation event, other 
RAD51 subunits bind at the end of the forming filament to build a long protein 
polymer defined as presynaptic filament (Bianco, Tracy et al. 1998). 
Another key regulator of the HR pathway known to directly regulate RAD51 
activity is BRCA2 (San Filippo, Chi et al. 2006). Indeed, multiple evidences 
underlines how this protein directly interacts with RAD51 and triggers ssDNA 
recognition and binding. Accordingly, Moynahan and collaborators 
demonstrated that, by introducing mutations in the BRCA2 gene, they could 
abolish the RAD51 foci formation, which directly reflects the synthesis of the 
presynaptic filament (Moynahan, Pierce et al. 2001). 
Subsequently, RAD51 catalyzes binding of the DNA duplex (forming the 
synaptic complex), strand invasion and pairing of the ssDNA with the 
homologous sequences in the genome (Morrical 2015). The homologous 
template invasion is allowed by the intervention of accessory factors such as 
Rad54, Rad54B, Rdh54 and Mnd1 (Li and Heyer 2009), allowing the consequent 
formation of the D-loop. Then, upon Rad54-mediated RAD51 removal, 
polymerase δ induces the elongation of the invading DNA strand and, upon 
disassembling of the synaptic complex, DSBs can be resolved by either DSBR or 
SDSA sub-pathway activation. 
 
1.1.2 Programmable nucleases as tool for precise gene modifications 
Gene editing, by definition, indicates the possibility to insert, eliminate or 
modify specific gene sequences in the genomes of living organisms. 
Nevertheless, trying to correct inherited mutations, knockdown specific genes 




inefficient process, far away from therapeutic applications. Because of this, 
there is a strong need for new strategies aimed at improving the efficiency by 
which gene editing occurs. The discovery of programmable endonucleases, able 
to introduce site specific DSBs inside eukaryotic genomes, dramatically 
changed the prospective of gene editing. Zinc-finger endonucleases (ZFNs), 
transcriptional activator-like effector nucleases (TALENs) and, more recently, 
the clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 system, 
are some examples of this technology. 
 
1.1.2.1 Zinc-finger endonucleases (ZFNs)  
Zinc-finger endonucleases are the first example of the manipulation of DNA 
binding modules, associated with nucleases, employed to introduce precise 
DNA cleavages inside eukaryotic genomes. The Cys2-His2 zinc-finger (ZF) 
domain represents a well-characterized DNA binding domain, normally 
expressed in eukaryotic genomes. The ZF is composed by 30 amino acids 
organized in a conserved ββα configuration (Beerli and Barbas 2002), able to 
recognize and bind 3 bp sequences at the α-helix surface. Due to the modular 
characteristics of this DNA binding domain, it results able to specifically 
recognize all the 64 possible triplets combination. Moreover, a variety of ZF 
modules can be link together in order to recognize longer DNA sequences 
(Bhakta, Henry et al. 2013). Consequently, the possibility to create custom high 
specific DNA binding modules and link them with nucleases presenting a 
cleavage domain, such as FokI, allow researchers to deal with a technology 
virtually able to target and cleave any DNA sequence. These tools can be 
employed to create nicks, but, in order to induce DSBs inside the genome, ZFNs 
work as a dimers, recognizing and cutting the preselected DNA strands 
depending on the different zinc-finger arrays. These tools have been largely 
employed for genome editing approaches and many modifications have been 
developed during the years to improve the DNA cleavage specificity and 
efficiency. As an example, in the paper of Guo and collaborators, the authors 




efficiency of DNA cleavage up to 15-fold if compared to the classical ZFNs (Guo, 
Gaj et al. 2010).   
 
1.1.2.2 Transcriptional activator-like effector nuclease (TALEN) 
endonucleases  
In nature, the TAL effectors (TALEs) are DNA binding proteins produced by 
specific bacteria. They are composed of 33-34 amino acids, which are highly 
variable in positions 13th and 14th. These two are defined as repeat variable di-
residues (RVDs) and result crucial for high specific nucleotide recognition (Boch, 
Scholze et al. 2009, Moscou and Bogdanove 2009). Due to their DNA binding 
characteristics, different TAL effectors can be linked together and fused with 
endonucleases (TALENs) to generate high specific DNA cleavages inside 
genomes. Hockemeyer and co-workers provided one of the first evidence 
regarding the possibility to introduce precise DSBs inside the human genome 
using the TALEN technology (Hockemeyer, Wang et al. 2011). These authors 
modified human ES and iPS cells, by targeting the PPP1R12C, OCT4 and PITX3 
genes using a TALEN approach and comparing the results with the ones 
obtained using the ZFNs technology (Hockemeyer, Soldner et al. 2009). As in 
Figure 4: ZNFs are the first example of the manipulation of DNA binding modules, 
associated with nucleases. They are employed to introduce precise DNA cuts inside 
virtually any sequence in the genome. The Cys2-His2 zinc-finger (ZF) domain 
represents a well-characterized DNA binding domain, normally expressed in 





the case of ZFNs, TALENs work as a dimer to introduce two DSBs, each one 
recognizing one specific DNA strand. 
 
 
Figure 5: Diverse TAL effectors, known to recognize specific nucleotides inside 
the genome, can be linked together and fused with endonucleases (TALENs) to 
generate high specific DNA cleavages. 
 
1.1.2.3 Clustered regularly interspaced short palindromic repeats 
(CRISPR)/Cas9 endonuclease 
1.1.2.3.1 History of CRISPR/Cas9 discovery  
The first annotation regarding CRISPR was published in the paper of Nakata and 
coworkers in 1987, when these authors recognized a particular set of 21-37 bp 
repeated sequences, interspaced by non-repetitive 32 bp spacers, in the E. coli 
iap gene, (Ishino, Shinagawa et al. 1987). Since then, the analysis of many other 
bacterial genomes has confirmed the presence of the same tandem repeats 
(40% of the sequenced genomes). For this reason, in the paper of Mojica and 
collaborators, these sequences were first classified as a unique family of 
clustered repeat elements (Mojica, Diez-Villasenor et al. 2000) and, in a second 
work, as CRISPR (Jansen, Embden et al. 2002). In the same publication, authors 
also showed the presence of conserved sequences adjacent to the tandem 
repeats, which were defined as CRISPR-associated (cas) genes. These 
publications lay the bases for the next classification of three different categories 
of the identified CRISPR system (type I-III). Furthermore, to understand the 
importance of the CRISPR system, an essential contribution was provided in 




demonstrated the extrachromosomal and viral-related origin of the spacer 
sequences (Mojica, Diez-Villasenor et al. 2005). Additionally, they also 
underlined how archeal cells expressing specific spacers were resistant to the 
infection of different phages. In the same year, the function of the protospacer 
adjacent motif (PAM), another CRISPR essential component, was also defined. 
Bolotin and collaborators discovered how the presence of a short conserved 3-nt 
sequence (PAM), was crucial to confer the type II Cas9 DNA cleavage specificity 
(Bolotin, Quinquis et al. 2005). 
Collectively, all these information allowed researchers to define the CRISPR 
system as a sort of bacterial immune response against viral infections (Pourcel, 
Salvignol et al. 2005). The first confirmation of this theory came from the work 
of Barrangou and coworkers, who, in 2007, confirmed the CRISPR system as a 
site-specific endonuclease, whose activity is controlled by the CRISPR spacers 
(crRNAs) (Barrangou, Fremaux et al. 2007). Three years later, the bacterial 
Figure 6: Thanks to the Waston-crick interactions between the gRNA, which 
corresponds to a crRNA fused with the tracrRNA and the target locus, the 
Cas9 can induce high specific DNA cleavage. Nevertheless it presents many 
limitations, it still results the most efficient tool to stimulate both precise 





mechanistic role of the CRISPR system was definitively clarified (Garneau, 
Dupuis et al. 2010). Then, in 2011, the role of another key component of CRISPR 
type II system biogenesis was elucidated. Delcheva and collaborators described 
the function of a trans-activating crRNA (tracrRNA) able to hybridize with the 
crRNAs and therefore allow the final maturation of the CRISPR array into a 
mature and active form (Deltcheva, Chylinski et al. 2011).  
Despite the great enthusiasm that was elicited by this novel site-specific DNA 
cleavage system, genome-engineering applications were still far to be explored. 
One of the first evidence in this respect of this came in 2011, when Siksnys and 
coworkers, trying to control the endonucleolytic activity of the CRISPR system, 
demonstrated the possibility to transfer the Streptococcus thermophilus type II 
CRISPR system into Escherichia coli (Sapranauskas, Gasiunas et al. 2011). A 
critical turning point came in 2013, when Cong and collaborators demonstrated 
the first successful adaptation of an engineered type II Streptococcus 
thermophilus CRISPR system to induce genome editing in mammalian cells 
(Cong, Ran et al. 2013). By using a single guide RNA (sgRNA), which corresponds 
to a crRNA fused with the tracrRNA, these authors were able to drive the Cas9 
DNA cleavage activity and therefore stimulate eukaryotic cellular NHEJ or HR 
repair pathways. 
CRISPR/Cas9 technology shows a series of advantages if compared with the 
previously established gene editing tools. It is very easy to customize, displays a 
very broad range of cleavage pattern and, most notably, the editing efficiency 
results much more improved, since target DNA recognition is mediated by 
nucleic acid hybridization rather than by protein-DNA binding, as it is the case 
for TALEN and ZNF. This also allows the simultaneous targeting of multiple 
genomic loci.   
 
1.1.2.3.2 Natural mechanism of action  
The first explanation of how the CRISPR system works inside bacteria cells came 
from the work of Mojica and collaborators, who, in 2003, showed how some 




inside P1 phage genomes. This observation was confirmed looking at the same 
correspondence between many other spacers and known viral sequences. Taken 
together, these data allowed researchers to postulate a theory by which the 
CRISPR system is as a sort of bacterial adaptive immune response against phage 
infection. In other terms, prokaryotes evolved a nucleic acid-based immunity 
system, by which the specificity is determined by the CRISPR spacers and the 
enzymatic activity depends on the Cas enzymes. After cell invasion, phages 
release their genome and, as a consequence, Cascade and Cas3 enzymes start to 
acquire specific spacers that are then loaded iton the CRISPR locus inside the 
prokaryotic genome. This phase, known as “adaptation”, represents the first 
step of the CRISPR-Cas mediated defense process and corresponds to the 
segregation of spacers between repeated sequences. There are two different 
forms of adaptation, depending on the origin of the spacer. If it derives from a 
not previously met phage the process is defined “naïve”. In contrast, when a pre-
existing evidence of viral infection is present, the adaptation is defined as 
“primed” (Fineran and Charpentier 2012). The Cas1 and Cas2 enzymes, both 
nucleases, control the spacer integration. In support to this notion, Yosef and 
coworkers demonstrated how the overexpression of Cas1 and 2 resulted in a 
significant increase in the spacer integration events. On the other hand, these 
authors also demonstrated that mutations in the active site totally abolish the 
adaptation process (Yosef, Goren et al. 2012). Cas1 and 2 work as a complex 
formed by a dimer of Cas2 that recognize two dimers of Cas1. Recent studies by 
Nunez and collaborators have defined how, in the E. coli Type I-E CRISPR 
system, the complex formed by Cas1 and 2 is able to integrate sequences into 
the CRISPR array using a retroviral integrase and transposase approach (Nunez, 
Lee et al. 2015). Moreover, Cas9 also participates in the integration process, 
possibly by driving the site-specific spacer integration. Finally, the adaptation 
also requires a spacer selection based on specific criteria. In support to this 
notion, it was demonstrated that the PAM sequence plays a key role also during 
this phase, allowing cells to discriminate between self and non-self (Mojica, 




transcript that has to pass through different maturation steps, depending on the 
different CRISPR system type (crRNA biogenesis and processing), before 
becoming active. During this step, the CRISPR RNA precursor (pre-crRNA) is first 
transcribed and then processed into the mature form by Cas proteins and other 
factors. 
By comparing the three types of CRISPR systems, they all share a series of 
similarities in crRNA conformation and processing. Types I and III both use Cas6 
as the key enzyme during crRNA maturation, excluding the Type I-C, which 
employs Cas5d (Nam, Haitjema et al. 2012). Nevertheless, the type II crRNA 
maturation is driven by a totally different mechanism that employs Cas9, 
cellular RNAse III and the base pairing with the tracrRNA (Deltcheva, Chylinski et 
al. 2011). The last step corresponds to the “interference”, which represents the 
combined action of crRNA and Cas proteins that recognize and cleave the phage 
DNA (Brouns, Jore et al. 2008). Both Type I and II systems employ the PAM 
sequence to avoid self-CRISPR array DNA cleavage and therefore to induce the 
non-self activation (Semenova, Jore et al. 2011). The mature crRNAs are loaded 
on the Cascade complex, which allows the unspecific DNA binding and scanning, 
searching for possible PAM sequences throughout the viral genome. Once the 
crRNA binds DNA, this causes a conformational change of the Cascade complex, 
leading to Cas3 activation (Wiedenheft, Lander et al. 2011). This enzyme is able 
to nick the target DNA, which then undergoes degradation (Westra, van Erp et 
al. 2012). In contrast, the type II system only requires the Cas9 activity, driven by 
the crRNA and tracrRNA complex. The crRNA forms a heteroduplex with the 
target DNA sequence, which is then cleaved thanks to the activity of Cas9 HNH 
and RuvC nucleolytic domains on the complementary and non-complementary 
strands (Nishimasu, Ran et al. 2014).  
 
1.1.2.3.3 Diversity between Cas9 orthologs 
Since its discovery, a high level of conservation of the CRISPR system was 
evident among different bacterial species. In order to investigate CRISPR 




BLAST approach to compare previously described Cas9 sequences with publicly 
available genome databases (Fonfara, Le Rhun et al. 2014). The results revealed 
the presence of 653 sequences corresponding to Cas9 orthologs, associated with 
347 different bacterial species. Consequently, the comparison of the cas gene 
sequences, the direction of the CRISPR array and the sequence of different 
tracrRNAs allowed researchers to recognize three different main groups of Type 
II CRISPR-Cas: type II-A, corresponding to the S. thermophilus or S. piogenes 
Cas9 enzymes; type II-B, referring to the F. novicida; type II-C, typical of P. 
multocida and N. meningitis. These findings confirmed how the type II CRISPR 
loci result largely variable between species, but largely conserved through the 
different groups (Chylinski, Le Rhun et al. 2013). 
Different Cas9 orthologs may also require different PAM recognition site. To 
characterize the different PAM motifs using the same BLAST approach, the 
group of Charpentier identified a number of conserved sequences downstream 
the target recognition site (Fonfara, Le Rhun et al. 2014). This information 
allowed researchers to elucidate the wide range of ortholog CRISPR systems 
characterized by specific Cas9 enzymes driven by specific dual-RNA structures 
and PAMs. The identification of novel Cas9 orthologs, showing different 
specificity, can therefore lay the basis for the generation of novel genome 
editing tools. 
 
1.1.2.3.4 Adaptation of Cas9 system to perform genome editing in eukaryotic 
cells  
Since the discovery of the CRISPR system as a programmable gene editing 
endonuclease (Marraffini and Sontheimer 2008), there has been growing 
interest in the possibility to modify Cas9 to transpose its activity in mammalian 
cells. Nevertheless, the huge biological differences between prokaryotic and 
eukaryotic cells may represent a great limit. The first evidences reporting a 
human codon-optimized S. pyogenes Cas9 (SpCas9), carrying nuclear 
localization signals, derived from the publications of Zhang and Doudna 




authors described how, by co-transfecting inside 293FT cells the tracrRNA and 
crRNA specific for the EMX1 locus together with the codon-optimized SpCas9 
and the RNAse III (SpRNAse III) genes, they were able to efficiently target the 
EMX1 locus. The generation of DSBs in the target site was then evaluated using 
the SURVEYOR assay. Moreover, the same authors also observed that the 
presence of the SpRNAse III was not mandatory to achieve crRNA maturation 
and therefore DNA cleavage. Additionally, they also performed the same gene 
editing assays using an engineered chimeric single guide RNA (sgRNA) structure 
generated by fusing the tracrRNA and crRNA sequences. The second main 
contribute to the field came from the publication of Doudna and collaborators in 
2013, when they described an efficient RNA-guided and site-specific DBS 
formation in CLTA locus using a type II Cas9 bacterial protein in human cells. In 
the same year, Church and collaborators demonstrated the possibility to target 
seven eukaryotic loci and underlined that both NHEJ and HR pathway are 
activated to repair the cleaved site (Mali, Yang et al. 2013). 
 
1.1.2.3.5 CRISPR/Cas9 system engineering  
Since the first gene editing application of CRISPR/Cas9 in eukaryotic cells, many 
other laboratories started employing this tool. Despite the increasing 
enthusiasm due to the number of advantages of this technique, different 
limitations were identified. Off-target effects, the generation of mosaicism, or 
the creation of multiple alleles due to the DSB repair through NHEJ, represent 
some example of these limitations. To overcome these drawbacks, different 
newly engineered versions of the Cas9 system have been proposed. Since it is 
known that the Cas9 enzyme cleaves DNA on both strands using two catalytic 
domains (HNH and RuvC) and creating blunt-ended DSBs, by mutating the 
sequence of one of these two, the laboratory of Zhang and collaborators 
demonstrated the possibility to generate a site-specific nickase, the activity of 
which causes a nick on one strand of the target DNA (Ran, Hsu et al. 2013). This 
modified Cas9 can therefore create single-stranded breaks, which are then 




Considering the great number of off-targets that characterize the classical Cas9 
activity, by generating a two Cas9 nickase system targeting opposite strands, 
Zhang and coworkers were able to introduce a site-specific DSB, minimizing the 
off-target activity and stimulating the HR-mediated repair. Additionally, in the 
paper published in 2014 from Joung and collaborators, in the attempt to 
minimize the off-target effects of Cas9, the authors showed a significant 
improvement in specificity using a truncated version of the gRNA combined 
with pairs of Cas9 nickases (Fu, Sander et al. 2014).  
Cas9 can be also used to alter the expression of specific genes, without inducing 
their knockout. An engineered version of Cas9, carrying mutations in HNH and 
RuvC-I sites and therefore defined as nuclease-deficient Cas9 (dCas9), was 
described in 2013 by Lim and collaborators (Qi, Larson et al. 2013). This group 
proved that the catalytically-dead Cas9 protein still maintained its DNA binding 
specificity leading to an alteration of the transcription of the targeted gene. This 
strategy, defined as CRISPR interference (CRISPRi), was then confirmed to 
repress targeted gene expression in E. Coli cells, without the identification of any 
off-target effects.  
On the other hand, different laboratories also explored the possibility to use the 
Cas9 enzyme to boost the transcription of target genes. Many CRISPR/dCas9-
mediated gene activation strategies have been developed to target specific 
promoters or induce the enhancing of regions of interest. One or many 
activation domains can be linked to the dCas9. Indeed, in the work of Gersbach 
and collaborators, they fused a SgRNA driven dead Cas9 with the VP64 acid 
transactivator domain, which corresponds to four repetition of the Herpes 
Simplex viral protein 16, and showed how its administration to human cells was 
able to specifically induce the expression of the target gene (Perez-Pinera, 
Kocak et al. 2013). Nevertheless, directly manipulate the epigenetic states at 
specific regions correlate with the transcription activation of target genes. 
Indeed, by fusing a dCas9 together with the transcription activator 
acetyltransferase p300, a protein driving the histone H3 lysine 27 acetylation, in 




OCT-4 transcription enhancing (Hilton, D'Ippolito et al. 2015). Moreover, 
another technology initially developed for imaging purposes, is the fusion of a 
dCas9 together with a protein scaffold carrying peptide epitope array (SunTag). 
Specific Abs fused with transactivators can recognize this array and 
consequently activate the transcription of the dCas9-targeted genes. This was 
proved in the paper of Gilbert and co-workers where they screened a list of 
sgRNAs matching in proximity of the transcription start site (TSSs) of 49 genes 
that correlates with cellular susceptibility to ricin (Qi, Larson et al. 2013). 
Nevertheless, fusing different transactivator to the Cas9 is not the only way to 
achieve targeted gene expression modulation. Indeed, in the paper of Zalatan 
and co-workers they connected to the sgRNA specific viral RNA sequences, 
which are recognized by MCP, PCP and Com RNA-binding protein. By fusing the 
VP64 transactivator to these proteins, they demonstrated a significant 
activation of target genes transcription. Moreover, by fusing to the same 
proteins repression domains (such as the KRAB domain), they underlined a 
corresponding transcription inhibition (Zalatan, Lee et al. 2015).  
Another important addition to the Cas9 technology system refers to the 
characterization of Cas9 from different bacterial species. In particular, a 
substantial progress came from the discovery of Cas9 from S. aureus (SaCas9), 
which displays similar efficiency as Cas9 from S. pyogenes but is significantly 
smaller in size (1053 amino acids vs. 1368 of SpCas9) (Friedland, Baral et al. 
2015). Indeed, many viral based approaches to deliver transgenes to cells, such 
as those taking advantage of the Adeno-Associated Vectors (AAV), have a 
precise space limitation for the inserted transgene they can accommodate. 
Friedland and collaborators showed that an optimized S. aureus Cas9 nickase 
sequence, together with a double expression cassette for sgRNA, efficiently fits 
within the AAV transgene packaging requirements (Friedland, Baral et al. 2015).  
Since the continuous expression of Cas9 inside the target cell in the presence of 
guide RNA can be detrimental in the long term, increasing the probability of 
unwanted off-target genome modifications, many laboratories are designing 




Bleris and collaborators proposed a self-inactivating transgene expression Cas9 
system (Moore, Spinhirne et al. 2015). These authors used an all-in-one plasmid 
coding for the Cas9 sequence, for the target DNA (mKate2) and for two gRNAs 
(T1 and T2). The U6 promoter drives expression of the two gRNAs, while Cas9 
and mKate2, separated by a 2A peptide, are transcribed starting from a CMV 
promoter. Upon HEK 293 cells transfection, both the mKate2 and the CRISPR 
system are transcribed. However, since the two gRNAs were designed to 
recognize sequences inside the mKate2 ORF, Cas9 activity consequently 
induced the vector degradation. Thus, this becomes a self-inactivating vehicle, 
able to control both the expression of desired transgenes and limit the Cas9 
activity inside the transfected cells. 
Again concerning the strategies aimed at limiting the off-target effects and 
improving the specificity of the CRISPR system, the Zhang laboratory recently 
identified a novel Francisella novicida U112 CRISPR system characterized by 
several interesting features (Zetsche, Gootenberg et al. 2015). It contains a 
putative class II CRISPR system, named Cpf1, as a single RNA-guided 
endonuclease able to functionally defend bacterial cells to plasmid interference. 
Cpf1 differs from the Cas9 protein both in structure and function, with potential 
significant advantages. First, different form Cas9, it presents only one RuvC-like 
endonucleolytic domain. Second, Cpf1 cleavage specificity is driven by a single 
stem loop in the CRISPR array (42 nt) and a short T-rich PAM domain, without 
the presence of the tracrRNA. This single RNA oligo therefore results much 
easier to synthesize if compared to the longer crRNA-tracrRNA duplex (110 nt). 
Furthermore, Cpf1 cleaves the double stranded DNA molecule producing 
staggered end termini. These represent a possible facilitation to mediate gene 
insertion through the NHEJ-repair, a mechanism much more efficient than HR in 
mammalian cells and, in particular, in post mitotic tissues. More recently, in 
2018, the Cereseto laboratory, to improve the enzyme specificity, without acting 
on the cleavage activity, identified, using a high-throughput yeast-based 
approach, new Cas9 variants (Casini, Olivieri et al. 2018). The most promising 




designed on-target activity (4-fold enriched), with a editing efficiency 
comparable with the WT enzyme.    
 
1.1.2.4  Genome editing using CRISPR/Cas9 
1.1.2.4.1 Ex-vivo Biomedical application of CRISPR/Cas9 system 
1.1.2.4.1.1 Genetic modified animal models  
The simplicity of the CRISPR/Cas9 system has immediately attracted 
attention for its potential use towards the generation of genetic modified 
animal models, able to mimic disease-causing mutations in patients. Due to 
its flexibility to target virtually any gene, the CRIRPR system is very suitable 
for these purposes. Indeed, the direct co-administration of the Cas9 protein 
complexed to the specific gRNA into the zygotes or early stage embryos of 
mice or rats can easily and efficiently generate specific knockout animals.  A 
very clear example of the feasibility of this process came from the work of 
Wang and coworkers, in which these authors showed the generation of mice 
carrying a single mutation in multiple genes, using the CRISPR/Cas9 system 
with no evident toxicity (Wang, Yang et al. 2013). By direct injection of Cas9 
mRNA and sgRNAs targeting Tet1 and Tet2 genes into mice zygotes, they 
were able to obtain 95% of the newborn mice carrying a biallelic mutation in 
both genes. This process therefore resulted easier and faster if compared to 
the cumbersome and time-consuming intercrossing between single-mutant 
mice.  
Conditional gene modification in mice and rats can also be achieved by 
providing embryos DNA templates for HR-mediated gene knock-in. 
Accordingly, Chu and collaborators reported in 2016 a 20% success rate for 
an 11 kb transgene insertion inside the Rosa26 locus obtained by direct 
injection in the C57BL/6 mice zygotes of a modified Cas9 mRNA, together 
with the gRNA and the homologous template (Chu, Weber et al. 2016). 
 




Another key application of this technology is the possibility to use Cas9 to 
specifically modify ex-vivo, for therapeutic purposes, human clinical cell 
samples, which are then re-administered to patients. T-lymphocytes and 
CD34+ hematopoietic stem cells are particularly suitable for his application. 
A first example of this use came from the work by Schumann and 
collaborators, in which these authors targeted the CXCR4 gene, which codes 
for a co-receptor essential for HIV cell entry (Schumann, Lin et al. 2015).  
Electroporation of the Cas9 enzyme and a gRNA targeting the CXCR4 into 
human CD4+ T-cells led to the knockdown of the receptor and the 
acquisition of resistance to HIV infection (Schumann, Lin et al. 2015).  
The same authors also demonstrated that the direct cell transfection of the 
ribonucleoprotein complex together with a single stranded oligo DNA 
template complementary to specific sequences of both CXCR4 and PD-1, a 
cell surface receptor known to be associated with inhibition of cancer cell 
killing, resulted in efficient knock-out genome modification (Schumann, Lin 
et al. 2015).  
This work laid the basis for the approval of an ongoing clinical trial that 
received green light in 2016, the purpose of which is to engineer CD4+ T-
cells, harvested from patients, with a Cas9-mediated ex vivo gene editing 
approach to induce expression of a T cell receptor (TCR) recognizing the NY-
ESO-1 tumor.  
More recently, the novel Cpf1 endonuclease has also been employed for 
correcting genetic mutations. The most frequent alterations leading to the 
development of Duchenne muscular dystrophy (DMD) consists of X-linked 
mutations that induce the skipping of three exons preceding exon 51, which 
interrupt the open reading frame (Bozkurt, Aguilar et al.) by juxtaposing out-
of-frame exons. In the attempt to correct this disease-causing mutation, 
Olson and collaborators administered Cpf1 endonuclease and the 
corresponding sgRNAs targeting the T-rich splice acceptor site of exon 51 
into DMD iPS-derived cardiomyocytes (CMs) (Zhang, Long et al. 2017). In 




by InDel introduction, laid to skipping of exon 51. This restored the reading 
frame allowed the production of an incomplete, but partially functional 
dystrophin protein.   
 
1.1.2.4.1.3 Genomic high-throughput screenings 
If compared with RNA interference mediated by the use of short harpin 
RNAs (shRNAs) or small interfering RNAs (siRNAs), the CRISPR/Cas9 system 
presents several advantages. Different from the transient mRNA 
degradation due to shRNAs/siRNAs interference, Cas9 mediated gene 
knockout produces the biallelic alteration of the genomic target sequence, 
and, consequently, its permanent silencing. Moreover, the CRISPR 
technology id easily applicable and has low cost, which is attractive for high-
throughput screening studies. In 2014, the group of Koike-Yusa published 
the results of a genome-wide sgRNA screening in mouse ES cells, aimed at 
identifying new silenced genes directly associated with the resistance 
against the Clostridium falciparum alpha-toxin (Koike-Yusa, Li et al. 2014).  
Since then, different set of sgRNA libraries have been generated in order to 
study different biological events. For example, Doench and collaborators 
generated a lentiviral-based sgRNAs library to study the knockdown of 
human or mouse cell-surface proteins (Doench, Hartenian et al. 2014). 
Furthermore, by using a catalytically dead Cas9 fused with a Krüppel 
associated box (KRAB) (a well described transcriptional repressor of RNA 
polymerase I, II and III) (Witzgall, O'Leary et al. 1994) and controlled by a 
doxocyclin-inducible promoter, Gilbert and coworkers expressed in K562 
cells a customized sgRNA library to identify targets regulating the resistance 
to the cholera toxin (Gilbert, Larson et al. 2013). The results obtained 
showed the enrichment and the loss of many sgRNAs, corresponding to the 
downregulation of specific genes possibly related with cholera toxin 
resistance and confirming the feasibility of the approach.  
 




Despite the CRISPR/Cas9 technology has been dramatically improved over the 
last years, still the gene editing technology needs further improvements. 
Nevertheless, there are cases in which the efficiency of the treatment may be 
sufficient to show an evident clinical effect. For example, monogenic recessive 
disorders caused by loss-of-function mutations, such as cystic fibrosis or DMD, 
may represent good candidates to be treated with genome editing approaches. 
Hereditary tyrosinemia type I (HTI) is another example of a genetic disease that 
can potentially be treated using the CRISPR/Cas9 technology. This condition is 
characterized by mutations in the fumarylacetoacetate hydrolase (Fah) gene, 
one of the key components of the tyrosine degradation process, which produces 
the toxic accumulation of this amino acid in the blood. To correct these 
alterations, Grompe and coworkers demonstrated how, in a mouse model of 
HTI, it is possible to restore the WT sequence of the Fah gene using Cas9 
induced HR-mediated knock-in in the liver of adult mice (Yin, Xue et al. 2014). 
Upon treatment, only 0.4% of the hepatocytes was shown to express the 
corrected Fah sequence; nevertheless, this was sufficient to significantly 
ameliorate the pathological phenotype.  
Another example of a potential good candidate for a gene editing treatment 
was provided by Regan and coworkers, who demonstrated how the Cas9-
mediated permanent knock-out of the Proprotein convertase subtilisin/kexin 
type 9 (PCSK9) in mice led to 40% decrease in plasma cholesterol (Ding, Strong 
et al. 2014). These findings further confirmed the protective effect of PCSK9 
depletion against the development of cardiovascular diseases. Different from 
the previous approach, in this work the authors used Cas9 to inactivate the 
target gene, a process that results much more efficient if compared to precise 
HR-mediated gene insertion. Nevertheless, also in Autosomal dominant 
mutations can be considered good targets for possible CRISPR-based gene 
correction therapies. Indeed, in the publication of Bakondi and collaborators, 
they proposed a Cas9-based approach to successfully treat S334ter-3 rats, a 




Despite the great progresses in improving the efficiency and precision of the 
CRISPR technology, a major limitation still remains in vivo delivery. To develop a 
plasmid-free transfection method, the group of Kim and coworkers developed a 
gRNA and Cas9 system fused with cell penetrating peptides (CPPs) 
(Ramakrishna, Kwaku Dad et al. 2014). The treatment of different human cell 
lines with this technology led to the efficient knockdown of the target genes, 
with reduced number of off-target events.  
Another optimized CRISPR delivery approach was reported by Beisel and 
collaborators, who described a nanoparticle-based delivery system (Sun, Ji et al. 
2015). The complex of the sgRNA and the Cas9 enzyme was loaded inside DNA 
nanoclews, which are DNA-based nanoparticles, coated with polyethylenimine 
(McGill, Ismail et al.), which allowed the endosomal escape thanks to its positive 
charge. Other approaches to vectorize the CRISPR system derived from the 
work of Mangeot and collaborators (Mangeot, Risson et al. 2019). In this study 
they proposed a lentiviral-based approach to package the CRISPR system and to 
treat primary cells, embryos and animal models. This technology, called 
Nanoblades, resulted much more efficient at inducing dsDNA breaks if 
compared with lipids-based or elettroporation approaches, both in tumor cells 
(U2OS) or iPS cells. 
Despite these examples represent an important progress in this field still the 
most promising CRISPR delivery method in vivo remains the use of viral vectors, 
such as AAVs. Indeed, due to their favorable characteristics, such as high 
transduction efficiency of many tissues and low immunogenicity, these vectors 
can be exploited to efficiently transfer the Cas9 gene and different gRNAs into 
many cell types. Of interest, AAVs have also been employed before the 
discovery of CRISPR for different gene editing approaches. As an example, an 
endonuclease free approach was proposed by Kay and collaborators in 2012 
(Wang, Lisowski et al. 2012). The purpose of this study was to inset the human 
Fah transgene into the safe harbor 28S rDNA locus of Fah-/- HTI mice by HR. 
(Paulk, Wursthorn et al. 2010). These investigators packaged the rDNA-hFah 




hepatocytes. Upon treatment with NTBC, a drug known to induce liver damage 
in the HTI mouse model and consequent fast hepatocytes proliferation, AAV8 
were administered to mice. The episomal non-integrating viruses were diluted 
and therefore lost, while the recombined sequences were selected as resistant 
cells and the site-specific integration was confirmed by PCR. By repeating the 
AAV8 administration, the investigators were therefore able to improve the 
number of hFah+ hepatocytes until the functional restoration of the liver 
physiological parameters.  
More recently, several groups started to employ AAVs to transfer the Cas9 
system inside the desired tissues. Rivera and collaborator reviewed the 
possibility to treat mdx mice, the mouse model for DMD, with the Cas9 
technology to restore the production of the protein (Nelson, Hakim et al. 2016). 
These authors proposed a strategy based on the NHEJ-mediated removal of 
exon 23 of the dmd gene, which carries a nonsense mutation that induces the 
premature block of protein production. The possibility to remove exons from the 
coding sequence can therefore restore the correct frame and allow the 
production of an incomplete micro-dystrophin. This strategy generates a less 
severe form of the pathology, defined as Becker muscular dystrophy (BMD). By 
using an AAV8 vector coding for the SaCRISPR/Cas9 system and another AAV8 
vector carrying two sgRNAs against intron 22 and 23, they were able to induce 
the skipping of the exon 23. This gene editing approach can restore the 8% of 
the dystrophin protein levels, with a 67% of DMD-positive myotubes. 
Accordingly, the muscle histological parameters, such as morphology, fibrosis, 
number of infiltrating macrophages and the consequent inflammation, were 
also significantly improved after the CRISPR treatment. Finally, the strength 
parameters, such as twitch and the tetanic force were also improved, confirming 
the beneficial effect of the AAV-mediated Cas9 gene editing in this particular 
pathological context. This NHEJ-mediated approach can therefore be applied to 
many mutations occurring in the dystrophin gene just by generating precise 




Since the administration of the Cas9 using AAV determines its prolonged 
expression, to limit the generation of possible off-target mutations other groups 
have developed a combined delivery method using both viral and non-viral 
vectors. An example of this approach can be found in the paper of Wu and 
coworkers, where these investigators described the possibility to treat a 
hereditary form of tyrosinemia (HTI) by a nanoparticle-mediated Cas9 delivery 
combined with the AAV-mediated expression of the sgRNAs and the template 
for correction (Yin, Song et al. 2016). The feasibility of this approach was tested 
in a mouse model of the human pathology, characterized by a mutation in the 
Fah gene, which leads to splicing alterations. The results from one single 
administration of the combined treatment in adult mice confirmed the 
restoration of the correct splicing of Fah gene in 6% of the hepatocytes.  
Based on these first successful applications in vivo, a number of monogenic 
conditions can be considered for CRISPR/Cas9-mediated repair, especially when 
a low efficiency of gene editing may still be clinically relevant. Of note, 
correction through NHEJ can be considered in virtually all cell types provided 
that a suitable gene delivery system is available. On the contrary, gene editing 
by HR and thus precise gene editing is conceptually limited to cycling cells. 
 
1.2 Adeno-Associated virus (AAV) 
Adeno-Associated virus (AAV) is a single-stranded DNA Parvovirus that became 
very popular in the last few decades with the advent of gene therapy. 
The first evidence of the existence of AAV came from the experiments of 
Atchison and collaborators, who, in 1965, identified a new viral contaminant of 
Adenoviral preparation (Atchison, Casto et al. 1966). Despite AAV was shown to 
grow together with Adenovirus, there were no identified biological similarities 
between them. AAV was classified as a dependovirus, due to the requirement of 
the presence of a helper virus, such as Herpesvirus (Georg-Fries, Biederlack et al. 
1984) or Vaccinia virus (Schlehofer, Ehrbar et al. 1986), in addition to 
Adenovirus, to achieve a functional infection. Indeed, it is known that without 




chromosome 19 (19q13.4), defined AAVS1, where it persists indefinitely in a 
latent form (Berns and Linden 1995). Of note, AAVS1 represents only 10% of the 
all the possible integration sites in the human genome; indeed, many other 
random integrations have been described (Huser, Gogol-Doring et al. 2010, 
Huser, Gogol-Doring et al. 2014). In contrast, during a productive infection, the 
AAV genome persist in an episomally concatamerized form and activates the 
viral gene expression (Cheung, Hoggan et al. 1980).  
In nature, many different AAVs have been identified over the years and 
classified depending on their different infection specificity. Several serotypes 
were shown to efficiently infect specific tissues depending on their peculiar 
capsid protein composition. The first evidence reporting AAV as a possible gene 
transfer tool came from the publication of Tratschin and coworkers, in which 
these investigators demonstrated how this virus was able to allow the 
expression of the prokaryotic chloramphenicol acetyltransferase (Huser, Gogol-
Doring et al.) gene in HEK 293 cells (Tratschin, West et al. 1984). Many of the 
information that we know about the AAV structure, genome and intracellular 
trafficking came from the study of AAV serotype 2 (AAV2). Indeed, this is also 
the first AAV that was engineered to produce non-replicative viral particles 
(Samulski, Berns et al. 1982). Due to their favorable characteristics, such as the 
absence of a recognized pathology induced in humans, the low immunogenicity, 
the ability to infect wide range of tissues, especially post-mitotic tissues, and the 
long lasting transgene expression, AAV appeared perfectly suitable to be used 
for the development of a gene transfer vector. Over the years, recombinant 
AAVs have been engineered to transduce with high efficiency both cells in vitro 
or tissues and organs in vivo. According to the wide range of possible 
applications, many groups started to employ AAV to induce virtually life-long-
lasting expression of the desired transgenes, for both basic research purposes 
and in clinical trials.  
The first evidence reporting the possible clinical impact of AAV-based treatment 
came from the paper of Buch and collaborators, who described a safe AAV-




condition is caused by mutations in the RPE65 gene, coding for a key 
component of phototransduction process (Buch, Bainbridge et al. 2008). These 
investigators confirmed in several animal models of inherited retinal disorders 
the efficient AAV-mediated RPE65 transgene transport inside the retina, with a 
consequent improvement of the vision, without the identification of side effects. 
These proof-of-concept experiments laid the basis for the first clinical trial, 
where young LCA patients were treated with AAV2 coding for the WT form of 
the RPE65 cDNA. One year after treatment, patients did not develop any 
adverse reactions against the virus, showing indeed a strong improvement in the 
visual sensitivity (Cideciyan, Hauswirth et al. 2009). These publications laid the 
basis for the further Food and Drug Administration (FDA) approval in 2018 of the 
AAV2-hRPE65v2 based therapy, to cure biallelic-mutation associated retinal 
dystrophy, with the name of Luxturna.  
During the years many other clinical trials started to use AAV for the treatment 
of several pathologies, such as haemophilia B (Nathwani, Reiss et al. 2014), 
Alzheimer’s disease (Mandel 2010), Parkinson’s disease (Christine, Starr et al. 
2009), Duchenne muscular dystrophy (Rodino-Klapac, Chicoine et al. 2007) or 
familial lipoprotein lipase deficiency (LPLD).  
The first AAV-based medical product that received the approval from the 
European commission to be commercialized in the Western world, under the 
name of Glybera (Salmon, Grosios et al. 2014), was an AAV1-based drug, coding 
for lipoprotein lipase (LPL), which was developed for the treatment of LPLD, a 
rare disease leading to an accumulation of triglycerides in the plasma and 
eventually fatal pancreatitis (Santamarina-Fojo, Haudenschild et al. 1998). 
Nevertheless, after few years, it was recalled from the European market due to 
its high cost. More recently, in 2019, another AAV-based therapy received the 
FDA approval for the treatment of Spinal Muscle Atrophy (SMA), under the 
name of Zolgensma. SMA is caused by the loss or the mutation of SMN1 gene, 
coding for SMN protein, a component of SMN complex, which plays a critical 




pre-mRNA splicing process. Zolgensma is an AAV9-based therapy targeting the 
motor neurons and codifying for the WT sequence of SMN1 gene.   
Currently, over 230 clinical trials using AAV are listed in the Wiley Gene Therapy 
Clinical Trial Worldwide Database (http://www.abedia.com/wiley/).  
 
1.2.1 Biology of the wild type Adeno-Associated Virus  
AAV is characterized by a single-stranded DNA genome of approximately 5 kb of 
size. It was classified in the Parvovirus family and Dependovirus genus due to its 
requirement of the presence of a helper virus to achieve productive infection. 
Therefore, this characteristic distinguishes AAV from other parvoviruses that are 
able to replicate independently (Galev, Afanas'ev et al. 1989).  
The first characterization of the AAV genome structure was provided by 
Srivastava and Lusby, who defined it as composed by two open reading frames 
(ORFs) flanked by two 145-nt regulatory elements (inverted terminal repeats, 
ITRs) (Lusby, Bohenzky et al. 1981, Srivastava, Lusby et al. 1983).  
By mutating the AAV genome, Tratschin and collaborators first demonstrated 
the specific roles of the two ORFs in viral infection (Tratschin, Miller et al. 1984). 
Alternative splicing of the first ORF (Rep) generate 4 mRNAs, coding for 
essential non-structural proteins (Muller, Kaul et al.)ANNO (Trempe and Carter 
1988). These are critical for viral replication, viral DNA integration into the host 
genome and gene expression (Senapathy, Tratschin et al. 1984). Moreover, 
these investigators also described an essential role of the Rep proteins in 
enhancing AAV promoters in the presence of a helper virus infection or exerting 
an inhibitory effect in its absence (Trempe and Carter 1988). More precisely, the 
Rep genes codes for Rep78, Rep68, Rep52 and Rep40, whose transcription 
requires two different promoters, P5 and P19. Rep78 and 68 mRNAs starts from 
the P5 promoter, while Rep52 and 40 require the P19 promoter (Marcus, 
Laughlin et al. 1981). The former two proteins were identified to play a central 
role in all the life cycle of AAV by also regulating its DNA integration into the 
chromosome 19 of the host genome (Young, McCarty et al. 2000). In contrast, 




2001). The second ORF, defined as Cap, instead codes for 3 structural protein-
coding genes (VP1, VP2 and VP3) and one additional protein essential for capsid 
assembly (Ramakrishna, Kwaku Dad et al.). At difference from the first ORF, the 
transcription of the three VP genes is regulated by one single promoter (P40) 
and the 3 capsid proteins are generated primarily by alternative splicing a non-
canonical ACG translation start codon for VP2 (Becerra, 1988; Trempe and 
Carter, 1988). The three distinct protein products share the C-terminus sequence 
that corresponds to VP3. The relative abundance of the individual proteins 
determined the stoichiometry of 1:1:10 of VP1, VP2 and VP3 in assembled 
capsids, respectively (Kronenberg, Kleinschmidt et al. 2001).  
 Additionally, the Assembly-Activating protein (AAP), required for the correct 
capsid assembly (Naumer, Sonntag et al. 2012), becomes stable upon VP3 
protein expression and represents a scaffolding protein able to interact with Cap 
proteins to trigger the correct organization of the viral particle formation 
(Sonntag, Schmidt et al. 2010). The AAV genome also contains two 145-bp long 
T-shaped harpin sequences, flanking the already described ORFs. These are 
essential for all the functional steps of viral live circle (Ashktorab and Srivastava 
1989). As already mentioned before, Rep78/68 play a critical role the absence of 
helper virus infection. Indeed, it was demonstrated that they negatively regulate 
the AAV promoters and induce latency. Despite this process does not alter the 
host-cell viability, it induces the activation of specific cellular genes that make 
cells more sensitive to DNA damage agents, probably due to the low levels of 
Rep protein production (Marcello, Massimi et al. 2000).   
 
1.2.2 Generation of recombinant AAV (rAAV) 
 Due to their favorable characteristics, over the last three decades there has 
been a progressive interest in the possibility to modify the AAV genome and 
capsid structure for gene therapy applications. In fact, it was demonstrated that 
the viral genome, cloned into a plasmid, was capable of packaging and 
formation of an infectious viral particle and that, in principle, any sequence 




obtain a recombinant vector able to transduce specific cell lines and tissues the 
AAV genome was modified. Different from the genome of a WT AAV, 
recombinant vectors typically contain, between the flanking ITRs, a promoter 
followed by a transgene expression cassette and the regulatory sequences. 
Therefore, the only parts of the AAV genome that remains unmodified are the 
two ITRs, since these are crucial components of viral genome packaging and 
intracellular processing. Noteworthy, since the Rep ORF is essential to achieve 
viral DNA integration inside the host genome, its elimination generates vectors 
able to persist only in an episomal and concatamerized form. Nevertheless, in 
order to achieve the functional transgene expression, the ssDNA sequence of 
recombinant vectors has to be duplicated thanks to the activity of an 
endogenous DNA polymerase. This crucial phase was described as a rate-
limiting step for the successful rAAV transduction (Ferrari, Samulski et al. 1996). 
Trying to overcome this limitation, self-complementary AAV (scAAV) was 
engineered from the natural occurring AAVs. This is characterized by a self-
hybridizing genome, able to create a double-stranded (ds) DNA directly through 
Watson-Crick interaction. Therefore, this class of vectors does not require the 
intervention of the cellular DNA polymerase for dsDNA conversion. Therefore, 
scAAVs was reported to be more efficient at transducing cells, generating higher 
levels of gene transfer in several tissues, such as brain, liver or retina (McCarty, 
Monahan et al. 2001, Petersen-Jones, Bartoe et al. 2009). The two flanking WT 
ITRs and a mutated ITR in the center compose the genome of scAAV vectors. 
Removing the terminal resolution site (Petrs-Silva, Dinculescu et al.) to a WT ITR 
generates this peculiar DNA structure. DNA replication in these vectors starts 
from a binding site present on the 5’ WT ITR, then, the absence of the TRS, 
allows the synthesis of DNA through the modified ITR and again on the opposite 
strand until the enzyme reaches the 3’ WT ITR. Despite scAAV is more efficient 
at transducing several cells and tissues, the limited packaging capacity, 
corresponding to half of the conventional rAAVs capacity (2.1 kb compared with 
4.7 kb of conventional ssAAV), represents a main weakness of this vector. 
 




The first isolated serotype was AAV serotype 2, which was recognized as a 
contaminant of Adenoviral preparations. From its discovery, over the years, 
many other serotypes were identified. These share many genome structure 
feature however differ by peculiar serological profiles they elicit in the host due 
to different capsid protein structure (Hoggan, Blacklow et al. 1966, Rutledge, 
Halbert et al. 1998, Gao, Alvira et al. 2002, Gao, Vandenberghe et al. 2004). The 
first step in the infectious cycle of AAV is the recognition of specific membrane 
structures, which is essentially mediated by the Cap proteins.  AAV2, AAV3 and 
AAV13 recognize heparan sulfate proteoglycans; AAV1, AAV4, AAV5 and AAV6 
bind N-linked or O-linked sialic acids, while AAV9 was shown to bind galactose 
residues (Wu, Asokan et al. 2006, Shen, Bryant et al. 2011). Consequently, the 
different identified serotypes show specific infection profiles. AAV8 and AAV9 
were shown to be more efficient vector for hepatocytes transduction (Ohashi, 
Nakai et al. 2005), while AAV9 and AAV6 efficiently transduced the airway 
epithelium (Halbert, Allen et al. 2001). The brain can be efficiently transduced by 
several AAV serotypes (AAV1, 4, 5, 7 and 8). In the study of Inagaki and 
coworkers, these authors demonstrated efficient pancreas transduction using 
AAV1, AAV8 and AAV9 (Inagaki, Fuess et al. 2006). Noteworthy, the heart is one 
of the most permissive tissues, since several AAVs (AAV1, 6, 8 and 9) can 
efficiently transfer genes into cardiomyocytes. To date, 13 primate AAV 
serotypes have been identified and many others were artificially generated in 
the laboratory by fusing different capsid components. Furthermore, trying to 
improve transduction efficiency in different tissues, many chimeric viral particles 
have been engineered by combining the same genome with different AAV 
capsids. To create new recombinant capsids, Petrs-Silva and collaborators 
isolated new variants from capsid libraries (Petrs-Silva, Dinculescu et al. 2009), 
obtained with different methods. For example, to generate the first capsid 
library, the laboratory of Muller and coworkers used viral particles loaded with 
random peptides on their surface (Muller, Kaul et al. 2003). Libraries can also be 
generated using other strategies, such as random mutation of the Cap gene, 




example of an engineered vector comes from the paper of Zhong and 
collaborators, who described the generation of a more efficient AAV thanks to 
the substitution of a specific tyrosine in the capsid proteins with a phenylalanine. 
With this approach, these investigators generated a 30 time-more efficient 
AAV2 compared to the canonical serotype 2 vector (Zhong, Li et al. 2008).   
 
1.2.4 Intracellular processing  
To understand all the possible limitations directly associated with a successful 
transduction, it is very important to underline all the critical steps associated 
with AAV infection (Figure 7). As outlined above, specific serotypes can infect 
specific tissues depending on the peculiar proteins recognized on the cellular 
surface. For example, starting from binding to membrane heparan sulfate 
proteoglycans (HSPGs), AAV2 is rapidly internalized by the cells through 
clathrin-mediated endocytosis (Xiao and Samulski 2012). The clathrin vesicles 
then fuse with the endosomes, and AAV2 remains there until the acidification of 
the compartment. This event consequently induces the exposure, by the viral 
particles, of the N-terminus of the VP1 capsid protein, which contains 
phospholipase activity and facilitates endosome escape. Once viral particles 
reach the cytosol, they need transport into the nucleus. For this purpose, AAV 
contains two nuclear localization signals (NLS) on both the VP1 and VP2 capsid 
proteins, which allow full-packaged capsids nuclear internalization. Moreover, 
Nicolsoln and Samulski demonstrated how the nuclear pore complex (NPC) and 
importin-β are also essential for AAV nuclear entry (Nicolson and Samulski 
2014). Despite this available information, this phase of the viral life cycle still 
remains one of the key limiting step for viral transduction, as it can also be 
concluded from the paper of Bartlett and coworkers, who demonstrated how 
viral particles accumulate in perinuclear regions (Bartlett, Wilcher et al. 2000). 
The first report on the visualization of the viral internalization steps in real time 
was provided the work of Lux and collaborators, who substituted the AAV2 WT 
VP2 protein with a GFP-VP2 (Lux, Goerlitz et al. 2005). There are two different 




coworkers showed that AAV particles nuclear entry was not dependent on the 
active transport through the NPC (Xiao, Warrington et al. 2002). In contrast, in 
2014 Nicolson and Samulski demonstrated how the internalization was 
triggered by an active importin-β mediated mechanism (Nicolson and Samulski 
2014). Additionally, it is not clear whether particles uncoating happens outside 
the nucleus, in the perinuclear area, or inside the nucleus (Johnson and Samulski 
2009), however it is known that all the crucial components for dsDNA 
conversion are located inside the nucleus (Hansen, Qing et al. 2001). 
Once AAV reaches the nucleus its genome still needs to be converted from 
ssDNA to dsDNA and this corresponds to another rate-limiting step to achieve 
an efficient viral transduction (Ferrari, Samulski et al. 1996). Indeed, AAV 
genomes can be recognized from the DNA damage response (DDR) proteins. In 
fact, as first shown by our laboratory, the viral genomes physically interact with 
the cellular DDR MRN complex (Cervelli, Palacios et al. 2008). To demonstrate 
this, by infecting cells with a LacR-GFP and an AAV coding for LacO target sites 
Cervelli and coworkers were able to observe the viral genome conversion in 
specific foci inside the nucleus, which overlapped with those of DDR proteins. 
Since it is known that post-mitotic cells present very low levels of DDR protein 
expression, this observation can explain why AAV preferentially infects post-
mitotic tissues if compared with replicating cells. Indeed, Lovric and 
collaborators demonstrated how AAV transduction efficiency of CMs 
progressively increased after birth during CM maturation and correlated with 






Figure 7: Graphic representation of AAV intracellular trafficking. First, 
depending on the serotype, vectors bind their receptor and co-receptor complex 
and, after endocytosis, enter into the target cells. Different pathways are 
responsible of AAV internalization, for example CLIC/GEEC endocytosis, 
clathrin-mediated endocytosis (CCP) or caveolar endocytosis CAV). After this 
step, AAV vectors accumulate in the trans-Golgi (TGN), probably through a 
retrograde transport pathway that involves the endosome and its maturation 
from early to late endosome. During this step, the capsid conformation changes 
and vectors are released form the Golgi to the cytoplasm thanks to the exposure 
on the surface of the phospholipase A2 (PLA2) domain. After this step, AAVs 
enter into the nucleus through the nuclear pore complex (NPC) and importin-β, 





1.2.5 AAV production 
Several techniques have been developed over the years to generate 
recombinant AAV vectors. One possibility is to employ mammalian cells, using a 
double/triple plasmid transfection procedure using a protocol that has been 
optimized in order to minimize the generation of WT particles.  
Typically, HEK 293 cells are transfected with two plasmids coding for the Rep 
and Cap genes and for the desired transgene, flanked by the two ITRs. Since the 
Rep and Cap plasmid does not contain the ITRs, no WT particles will be 
produced; on the other hand, only the particles bearing the desired transgene 
are synthesized. This procedure results very efficient for the production of any 
serotype just by modifying the cap genes of choice, carrying any desired 
transgene flanked by the two IRTs (Laughlin, Tratschin et al. 1983). 
Nevertheless, to achieve a massive rAAV production, a combined infection with 
a helper virus, such as Adenovirus, is needed. This corresponds to a limitation of 
the technique, since it also leads to the production of Adenoviral particles. In 
order to avoid the production of helper-virus particles, another plasmid, coding 
for all the key Adenoviral genes (E4, VA and E2a), can be transfected. Since this 
third plasmid does not contain any virulent gene, it results completely safe and 
non-infectious, coding only for the viral genes essential for AAV synthesis. Due 
to its simplicity, plasmid transfection still remains the most used method to 
synthesize AAV particles. Moreover, it is also a very fast procedure, since AAV 
particles can be harvested at 48-72h post-transfection. The subsequent 
purification steps are aimed at both eliminating contaminating cell debris and 
recovering only capsids containing the viral DNA, thus eliminating the 
considerable proportion of empty capsids generated by the cells. This can be 
typically achieved by cesium chloride (CsCl) density gradient centrifugation. To 
increase the titer and purity of the preparation, this step can be repeated several 
times. Other techniques that can be employed are based ligand affinity 
chromatography (Zolotukhin, Byrne et al. 1999) however not all the AAV 






1.2.6 Limitation in the use of AAV 
Despite the wide range of possible applications, the use of AAV to transfer 
genes in vivo has some important limitations.  
 
1.2.6.1 immune response against AAV treatment  
Over the last years, several of the investigators who have used AAV vectors in 
clinical trials have started reporting the possible activation of an immunological 
response after AAV transduction. Zhu and collaborators underlined the 
correlation between AAV treatment and the innate immune system activation 
(Zhu, Huang et al. 2009). Other studies have underlined the possible production 
of neutralizing antibodies (NAb) from the adaptive immune system. This 
corresponds to a strong limitation of gene transfer efficiency, since NAb can 
completely inhibit AAV transduction (Manno, Pierce et al. 2006). In addition, 
these antibodies completely prevent the possibility of re-administering AAV 
vectors with the same serotype as the initial administration. Finally, a gene trial 
for hemophilia B, entailing liver gene transfer of the Factor IX cDNA, reported 
the long-term development of CD8 T cells against the AAV capsid protein (Hui, 
Edmonson et al. 2015) suggesting that incomplete processing and degradation 
of the capsid inside the transduced hepatocytes might lead to the generation of 
reactive cytotoxic lymphocytes that eventually clear the transduced cells. 
As a consequence, it appears very important to develop strategies trying to 
avoid the immune response system. Work from different investigators has 
indeed demonstrated the possibility to use rationally designed capsids, which 
generate less immunogenic serotypes during the first rAAV treatment (Li, 
Diprimio et al. 2012, Hui, Basner-Tschakarjan et al. 2013). In addition, to 
minimize the immune response against AAV, patients can be transiently 
immunosuppressed pharmacologically (Jiang, Couto et al. 2006). 
Despite this evidence of immune reactivity, it worth underlining that no severe 







1.2.6.2 Limitation in AAV tropism and transduction  
As previously described, AAV capsid proteins are responsible for cell target 
specificity of the different serotypes. Zincarelli and collaborators, in 2008, 
described how infection of different systemically delivered AAV serotypes 
(AAV1-9) in mice resulted in specific distribution and consequent transgene 
expression of each vector serotype inside the tissues. Furthermore, it was also 
demonstrated that different serotypes sharing the same target molecules infect 
the same cell types, however they can differ in their internalization rate 
(Pasquinelli, Reinhart et al. 2000). Despite many natural serotypes have been 
described infecting several tissues, not all the cell types can be transduced. For 
example, stem cells or endothelial cells, despite expressing receptor molecules 
that are common targets for different AAV serotypes are resistant to AAV 
transduction. This clearly underlines that the main determinants of AAV tropism 
lie beyond the capacity of the vector to be internalized, and involved subsequent 
steps such as endosomal escape, nuclear transport, de-capsidation and 
conversion from ssDNA to dsDNA, as also discussed above.  
 
1.2.6.3 Limited transgene packaging capacity  
Since the natural viral transgene packaging capacity is 4.7 kb, a large number of 
cDNAs can be delivered to cells and tissues using the AAV technology – the 
average size of human cDNAs is approximately 2.7 kb -. Grieger and Samulski, 
explored the possibility to synthesize capsids composed of only 2 Cap proteins, 
in order to permit a larger transgene loading capacity (Grieger and Samulski 
2005). The results from this study demonstrated that, by engineering different 
serotypes (AAV1-5), a maximum size of 6 Kb could be reached. Furthermore, 
Allocca and collaborators demonstrated the possibility to synthesize AAV 
particles carrying genomes of more than 8 Kb (Dong, Nakai et al. 2010). 
Nevertheless, a substantial lower infectivity was detected by using particles 




Wu and collaborators, who in 2009 demonstrated lower transduction efficiency 
of rAAV containing genomes larger than 5 kb (Wu, Yang et al. 2010). 
 
1.3 MicroRNA 
MicroRNAs (miRNAs) are small non-coding RNAs, coded by the genome of 
plants, animals and viruses, which have been discovered to post-
transcriptionally regulate gene expression. In humans, 1,984 microRNA 
precursors have been annotated, which correspond to 2,693 mature and active 
sequences (miRBase release 22.1, October 2018, http://www.mirbase.org). 
MiRNAs drive the process of RNA-interference, since, by direct base-pairing 
recognition of target mRNAs, they can silence the expression of their target 
genes through different mechanisms. In particular, they recognize specific 
sequences, often located in the 3’-UTRs of transcripts, both through perfect of 
imperfect base pairing with their “seed sequence”, located between nucleotides 
2 and 7 of 5’-UTR of mature miRNAs. This specific sequence is essential to 
trigger genes knockdown (Doench and Sharp 2004). It has been demonstrated 
that 60% of the human genome is directly regulated by the activity of miRNAs 
(Lewis, Burge et al. 2005); indeed, hundreds mRNAs can be regulated by a single 
miRNA (Friedman, Farh et al. 2009) and many miRNAs can repress a single 
gene. According to this information, miRNA are now considered as strong 
regulators of many physiological and pathological processes.  
 
1.3.1 MicroRNAs discovery 
The first discovered miRNA was described by Victor Ambros and collaborators, 
when these investigator were working on the identification of possible 
mutations in the genome of C. elegans, which were able to modify the growth of 
this nematode (Lee, Feinbaum et al. 1993). They discovered that the lin-4 gene 
encoded for two RNAs, of 22 and 61 nt. Instead of producing a protein-coding 
mRNA, the shorter RNA was found to give rise to a non-coding transcript able to 
inhibit lin-4 gene expression by directly targeting the 3’-UTR of the gene. 




development, Lin-7, was seen to produce a similar 21-nt non-coding transcript 
(Reinhart, Slack et al. 2000). Moreover, it was demonstrated that its sequence 
was complementary to the 3’-UTR of many other genes related with C. elegans 
development. Some years later, other 33 new miRNAs were identified both in 
invertebrate and vertebrate models as conserved regulatory sequences (Lagos-
Quintana, Rauhut et al. 2001).  
 
1.3.2 MicroRNAs biogenesis  
 The Biogenesis of miRNAs is a multi-step process that begins inside the nucleus 
and completes in the cytoplasm. MiRNAs precursor sequences are located in 
intronic and intragenic regions and their transcription is carried out by RNA 
polymerase II (Lee, Kim et al. 2004). This enzyme generates the so-called pri-
miRNAs, which correspond to long transcripts, presenting a harpin 
conformation, a cap-structure and a poly-adenylation site (Cai, Hagedorn et al. 
2004). Pri-miRNAs are then recognized by Drosha, one of the key components 
the miRNA biogenesis pathway. This enzyme is a RNAse III that, together with a 
Figure 8: miRNAs biogenesis corresponds to multi step process that begins 
inside the nucleus and completes in the cytoplasm. MiRNAs precursor 
sequences are located in intronic and intragenic regions and their 
transcription is triggered by the RNA polymerase II (Lee, Kim et al. 2004). 
This enzyme generates the so-called pri-miRNAs, which correspond to long 
transcripts, presenting a harpin confirmation, a cap-structure and a poly-




cofactor, called Pasha, modifies the pri-miRNA structure by converting it into a 
shorter RNA intermediate, defined as pre-miRNA (Lee, Ahn et al. 2003). These 
molecules of 70-130 nt of length maintain the harpin conformation, but present, 
at their 3’ ends, short overhang sequences (Lund, Guttinger et al. 2004). 
Subsequently, Exportin 5 recognizes the overhang sequences and allows the 
transport of pre-miRNAs into the cytosol. Here, they are recognized by Dicer, 
another RNAse III protein, that cleaves the intermediates into a double stranded 
RNA of 22 nt of length (Ketting, Fischer et al. 2001). Only one of the two strands 
will become the mature miRNA form, able to modulate gene expression, while, 
the other strand will be degraded.  
 
1.3.3 Mechanism of action of microRNAs  
After the conclusion of the maturation process, miRNAs are recognized by 
Argonaute proteins and consequently internalized inside the RNA induced 
silencing complex (Vatta, Mohapatra et al.) (Hammond, Bernstein et al. 2000). 
This protein complex therefore allows miRNAs to recognize and bind by 
Watson-Crick interaction, the target mRNAs and consequently induce their 
degradation and/or translation inhibition, depending on the perfect or imperfect 
base pairing with the seed-sequence. Consequently, looking at the different 
seed-sequences it is possible to clusterize the miRNAs into different families, 
targeting similar sets of mRNAs. In contrast, the other nucleotides are required 
for stabilization of the binding. An example of a miRNA family came from the 
paper of Pasquinelli and collaborators, who described the characteristics of the 
let-7 miRNA family (Pasquinelli, Reinhart et al. 2000). 
The perfect pairing with the seed-sequence then leads to the degradation of the 
target mRNAs, which is triggered by the Argonaute-mediated cleavage of the 
sequence (Llave, Xie et al. 2002). In contrast, the imperfect base pairing 
preferentially leads to the inhibition of mRNA translation, a mechanism that 
more frequently occurs in vertebrates. Eichhorn and collaborators demonstrated 
that mRNA destabilization is to the most common process by which miRNAs 




destabilization, the poly-A tail of the target mRNAs is removed thanks to the 
RISC-associated protein GW182, the activity of which activity is crucial for target 
gene silencing (Braun, Huntzinger et al. 2011).  
 
1.3.4 Modulation of endogenous microRNAs levels  
To better understand the role of miRNAs in both physiological and pathological 
processes, or to develop possible miRNA-based treatments, a possible approach 
consists in the artificial up or down regulation of their expression. With this goal, 
it is possible to use the so-called miRNA mimics technology, which uses double-
stranded RNA sequences, identical to the endogenous miRNAs, but chemically 
modified to force RISC to use only the desired miRNA strand. In contrast, to 
inhibit the expression of specific miRNAs it is possible to use miRNA inhibitors. 
These are usually small antisense sequences, able to efficiently bind the 
endogenous miRNAs by Watson-Crick interaction (Velu and Grimes 2012). As 
opposed to miRNA mimics, which are incorporated into the RISC complex and 
thus tolerate minimal structural variations, antisense miR can be modified by a 
portfolio of chemical modifications, including inclusion of locked nucleic acids 
(Michailidou, Beesley et al.), modifications of the backbone with 
phosphorothioate linkages at the 5’ or 3’ ends, and 2’-O-methyl or 2’-fluoro 
modifications of the bases (Davis, Lollo et al. 2006, Davis, Propp et al. 2009, 
Lennox and Behlke 2010). Among these, the LNA results the most efficient 
modification showing the highest affinity in complementary RNAs targeting. It 
corresponds to a class of bicyclic RNA analogues showing a N-type (C3’-endo) 
conformation chemically maintained by the addition of 2’-O, 4’-C methylene 
bridge (Stenvang and Kauppinen 2008). 
Several viral and non-viral based techniques have been proposed over the last 
years for the delivery of miRNA mimics into the cells both in vitro and in vivo 
(Pereira, Rodrigues et al. 2013). In our laboratory, Lesizza and collaborators, 
tried to identify the best non-viral in vivo delivery method to administer miRNA 
mimics (in the specific case, hsa-miR-590-3p and hsa-miR-199-3p) to the 




compared the efficiency of miRNA mimic transport of different lipids 
compositions after a single intracardiac injection, leading to the identification of 
the best protocol allowing the persistence of the mimics for 12 days after 
treatment using a lipofectamine-based commercial nanoformulation (Lesizza, 
Prosdocimo et al. 2017).  
Alternatively, the miRNA-encoded gene corresponding to ether the pri-RNA or 
the pre-miRNA can be embedded into a viral vector, most notably an AAV 
vector. This design permits the choice of a suitable promoter (constitutive or 
tissue-specific) and the prolonged expression of the miRNA. Using this approach 
however, both miRNA strands can be used by RISC from the precursor miRNA to 
generate the final effector molecule. Thus, in contrast with the use of synthetic 
miRNA mimics, the unwanted effect of the strand opposite to the one of choice 
is unavoidable. 
 
1.3.5 MicroRNAs target identification 
Since it is known that miRNAs can modulate the expression of several mRNA, 
trying to identify the miRNA targets is commonly a very demanding and 
complex process. A first approach takes advantage of bioinformatics prediction. 
Over the last years, many tools have actually been developed to 
bioinformatically predict miRNA targeting (Targetscan, miRanda, Diana, 
miRDB, RNA22), based on the sequence matching between the seed sequence 
and the 3’-UTR of genes. Still, even when considered collectively, these tools 
continue to remain largely imprecise in predicting the actual miRNA targets.  
Experimental techniques are clearly needed to identify the actual miRNA target 
genes. A first approach is commonly the analysis of the transcriptome in cells 
transfected with miRNA mimics or anyhow expressing the miRNA of interest. 
Since miRNAs act by downregulating their targets, the downregulated genes in 
the transcriptome include the miRNA direct targets. Unfortunately, a 
disadvantage of this approach is the fact that many down-regulated genes can 
be the result of an indirect effect, rather than being the real targets. Thus, the 




commonly achieved first by studying the putative target mRNA levels upon 
miRNA mimic transfection and then by validating the specific seed interaction of 
the miRNA with the target, by using segments of the mRNA target cDNA 
(commonly, the 3’-UTR) downstream a reporter gene (commonly, luciferase) to 
verify its effective downregulation upon miRNA transfection or expression (Jin, 
Chen et al. 2013). 
As previously mentioned, the activity of miRNAs requires the correct assembly 
of several molecules inside the RISC complex. Thus, miRNA target identification 
can also be attempted through biochemical techniques based on 
immunoprecipitation of this complex, followed by transcriptome analysis. 
Easow and collaborators proposed a cross-linking immunoprecipitation (CLIP) 
approach combined with the microarray analysis of the selected transcripts 
(Easow, Teleman et al. 2007). The CLIP technique permits crosslinking and 
stabilization of the RNA/proteins interactions and consequently facilitates the 
recovery of the mRNAs linked inside RISC. Moreover, to improve the specificity 
of the RNA/protein crosslinking, a method named PAR-CLIP was developed 
(Thomson, Bracken et al. 2011). This requires the random or site-specific 
integration of photoactivable nucleosides analogs inside the nascent RNAs of 
living cells in order to probe the RNA/protein interaction. Upon UV irradiation 
and protein immunoprecipitation, a 100- to 1000- fold increase in the RNA 
recovery was observed, compared to the classic CLIP techniques (Baigude, 
Ahsanullah et al. 2012). Finally, Orom and Lund proposed an alternative 
technique to determine the miRNA:mRNA interactions based on the 
administration of biotinylated miRNAs to the cells, followed by the isolation of 






1.4 Human genetic cardiovascular disorders, the clinical demand 
Genetic abnormalities have been largely recognized as one of the major 
etiological causes of cardiomyopathies. Indeed, in the last decade, high-
throughput sequencing analysis has revealed many pathological mutations 
present in both sporadic and familial cardiomyopathies (Herman, Lam et al. 
2012, Ware, Seidman et al. 2016). Historically, one of the first evidence of 
genetic cardiovascular diseases (CVD) derives from the studies of Lehrman and 
co-workers, who sequenced the low-density lipoprotein receptor (LDLR) gene in 
a patient affected by familial hypercholesterolemia and characterized by a 
homozygous mutation. Their results confirmed a 5 Kb depletion in the sequence 
of the gene (Lehrman, Goldstein et al. 1985).  A few years later, in 1989, other 
mutations in β cardiac myosin heavy chain were recognized as the main cause of 
hypertrophic cardiomyopathy (Jarcho, McKenna et al. 1989). A number of 
subsequent studies provided a comprehensive picture of the contribution of 
genetic mutation to cardiac disorders. Three main classes of human genetic 
cardiomyopathies can be considered as the main causes of inherited cardiac 





   
 
  
Figure 9: Schematic representation of the most frequent disease causing 
mutations. There are three main classes of genetic determined 
cardiomyopathies: a) Hypertrophic cardiomyopathies (HCM); b) Dilated 
cardiomyopathies (DCM); c) Arrhythmogenic right ventricular cardiomyopahies 
(ARVC). HCMs and DCMs are caused by mutations in genes coding for 
sarcomeric proteins, while ARVCs correlate with desmosome genes alterations. 





1.4.1 Hypertrophic cardiomyopathy  
Hypertrophic cardiomyopathies (HCMs) are one of the most prevalent classes of 
cardiac dysfunctions worldwide. They are characterized by an unexplained 
ventricular hypertrophy that can be clinically ranked from asymptomatic, until 
causing sudden cardiac death (SCD) (Maron, Towbin et al. 2006). It is typically 
considered as a single gene disorder and usually mutations concentrate on the 
genes encoding for sarcomeric proteins. The most frequent variants are present 
in two genes coding for the β-myosin heavy chain (MYL7) (Geisterfer-Lowrance, 
Kass et al. 1990) and the myosin biding protein C (MYBPC3) (Ho 2012). In 
particular, in MYBPC3, more then 180 mutations have been annotated, the 
majority of which correspond to frameshift or nonsense mutations. In particular, 
one frequent alteration is a G to A transition identified in the last nucleotide of 
exon 6 (Richard, Charron et al. 2003); this mutation, occurring in 14% of all HCM 
patients in Tuscany, is associated with a severe phenotype and a poor prognosis 
in humans. To study the molecular determinant of the disease and to develop 
new possible therapeutic approaches, the group of L. Carrier created a knock-in 
transgenic mouse carrying this particular human point mutation in the 
corresponding mouse exon 6 of cMyBP-C sequence. Using this model, the 
Carrier group reported that the G to A transition in the exon 6 induced the 
formation of 3 different mutant mRNAs with missense, nonsense and 
deletion/insertions mutations (Vignier, Schlossarek et al. 2009). In another paper 
(Gedicke-Hornung, et al. 2013) the same authors demonstrated that, by 
inducing the exclusion of exons 5 and mutated exon 6 through targeted 2’-O-
methyl phosphorothioate-(2OMePS)-antisense oligoribo-nucleotides (AONs), 
the alternative spliced mRNA gave rise to a functional protein. The systemic 
administration of an AAV9 vector coding for the AON to newborn Mybpc3- 
knocked-in mice prevented systolic dysfunction and the consequent ventricular 
hypertrophy (Gedicke-Hornung, Behrens-Gawlik et al. 2013). A number of other 
mutations have been reported as responsible for HCM development, including 
alterations in cardiac alpha-actin (ACTC1) (Morita, Rehm et al. 2008) and  




Despite the large range of HCM related mutations, the metabolic and 
mechanical dysfunction in all HCM cases relies on an increased energetic cost 
and an overall reduction of the sarcomeric power of contraction (Burke, Cook et 
al. 2016). 
 
1.4.2 Dilated cardiomyopathy 
Dilated cardiomyopathy (DCM) commonly presents with ventricular dilatation 
and impaired myocardial contractility. The disease is typically reported in 
combination with heart failure, but, in the case of genetic alterations, it is 
commonly associated with arrhythmia (Bozkurt, Colvin et al. 2016). The genetic 
background that correlates with the development of the disease is usually very 
heterogeneous. Many DCM-causing mutations in key protein coding genes may 
generate the disruption or dysfunctions of the sarcomere, alterations in the 
cytoskeleton, in mitochondrial components, in desmosomes or in the nuclear 
membrane.   
One of the first annotations in this direction comes from the paper of Gerull and 
collaborators, where they described specific alteration in the TTN gene, 
encoding for the giant muscle filament titin (Gerull, Gramlich et al. 2002). 
Moreover, in 2012 Herman and co-workers demonstrated that between 15 and 
25% of DCM cases are caused by truncations in TTN sequence (Herman, Lam et 
al. 2012).  Alterations in the same gene were also underlined in a subset of 
peripartum cardiomyopathies, usually associated with the LV function recovery 
after pregnancy (van Spaendonck-Zwarts, Posafalvi et al. 2014). Another class of 
DCM causing mutations includes non-synonymous variants of the LMNA gene, 
coding for lamin A and C. Approximately 6% of DCM cases show variants in the 
LMNA gene, with a presumed mechanism involving atypical and pathological 
mechanosignalling to the nucleus (Worman 2018). Autosomal dominant DCMs 
are commonly caused by missense or frameshift mutations that may occur 
throughout the coding sequence. This class of DCM shows a peculiar phenotype 
with sinus node dysfunction, atrioventricular block, atria and ventricular 




Another class of DCM-causing mutation was recognized in the PLN gene. It 
encodes for a 52 amino acids residue transmembrane protein 
(phospholambdan), that, if unphosphorilated, inhibits the activity of the 
sarcoplasmic reticulum Ca2+-ATPase (SERCA). Alterations in this gene are 
associated with lethal ventricular arrhythmias (Haghighi, Kolokathis et al. 2006).  
In the paper of Brauch and co-workers they identified RBM20 as another key 
mutated gene associated with DCM development (Brauch, Karst et al. 2009). 
Indeed, RBM20 regulates the splicing of the TTN gene (Guo, Schafer et al. 2012). 
Consequently, its mutation could represent a downstream molecular effect that 
clinically associates with the alterations occurring in the TTN variants.  
Moreover, alterations in ion channels were also described as associated with 
DCM development. Indeed, in the paper of McNair and collaborators they 
recognized missense mutations of SCN5A gene in familial cases of DMCs with 
high risk of arrhythmias (McNair, Sinagra et al. 2011). 
 
1.4.3 Arrhythmogenic right ventricular cardiomyopathy (ARVC) 
This class of diseases determines a progressive loss of the right ventricular tissue 
with its consequent substitution with fibrous and adipose tissue (Fontaine, Frank 
et al. 1984). The disease commonly correlates with the detachment of cardiac 
myocytes due to cardiac desmosome proteins aberrations. To date, mutations in 
5 genes have been described as causative of with ARVC development: 
plakophili2 (PKP2) (Gerull, Heuser et al. 2004), desmoplakin (Reilly, McKoy et 
al.) (Rampazzo, Nava et al. 2002), desmoglein-2 (DSG2) (Pilichou, Nava et al. 
2006), desmoscollin-2 (DSC2) (Syrris, Ward et al. 2006) and junctional-
plakophilin (JUP) (McKoy, Protonotarios et al. 2000). Despite not all the patients 
present one or more of these mutations, together they represent the 50% of the 
cases with an autosomal dominant transmission. 
 





In the last decade many gene correction strategies were optimized to 
implement possible clinical applications. The optimization of delivery systems 
(AAV), the designing of RNA-based approaches and the improvement of specific 
nuclease activity (CRISPR/Cas9), drastically paved the way towards the 
development of successful therapies in cardiac field.  
Moreover, an increased understanding of the genetic alterations leading to the 
development of several cardiomyopathies represents a grate starting point in 
the preclinical setting. Indeed, many of the heterogeneous disease causing 
mutations described in the precedent paragraphs represent monogenic and 
well-characterized alterations in structural and metabolic genes. Most of them 
are autosomal dominant or recessive nucleotides variants or little indels, which 
create in frame or out of frame sequence modifications. Moreover, the mutation 
in the stop codon or the generation of a premature stop codon can create 
truncated proteins. Usually, this category of alterations represents a perfect 
target for HDR-mediated gene correction. Nevertheless, this repair pathway is 
largely inefficient if compared with NHEJ in post-mitotic tissues, such as the 
heart. Indeed, NHEJ was recently exploited in many preclinical studies to induce 
a partial correction of disease causing mutations in the Duchenne Muscular 
Dystrophy (DMD). This pathology affects both heart and muscles and 13 % of 
patients present mutations in exons 48-50, with the consequent loss of the 
protein (Aartsma-Rus, Fokkema et al. 2009).  
Therefore, by the use of CRISPR/Cas9 and NHEJ-mediated genomic inactivation 
of the splicing inclusion sequence of mutated exon 51, it was possible to 
efficiently and permanently rescue the reading frame and expression of 
dystrophin in postnatal mdx mice and converting the DMD into a milder Becker 
Muscular Dystrophy (BDM) phenotype (Long et al 2017). A similar approach was 
also reviewed in the paper of Aartsma-Rus and collaborators, where they 
proposed an antisense oligonucleotide (Macera, Szabo et al.) to promote the 
exclusion of exon 51 (Aartsma-Rus, Straub et al. 2017). This molecule received 
the FDA approval for the treatment of DMD patients in 2016 under the name of 




known to alter its splicing and promoting the production of prelamin A (Lee, 
Nobumori et al. 2016). Furthermore, AONs were also used to induce an exon 
skipping in the genome of a mouse model carrying the Mybpc mutation to 
produce a different transcript with the consequent improvement in cardiac 
function (Gedicke-Hornung, Behrens-Gawlik et al. 2013).  
Nevertheless, HDR still remains the gold standard for precise gene correction. 
Despite it is clear that this pathway infrequently occurs in post-mitotic tissues, 
CRISPR/Cas9-based gene editing approaches demonstrated a successful HDR-
mediated dystrophin correction in a fraction of post-mitotic myofibers of a DMD 
mouse model (Bengtsson, Hall et al. 2017). Moreover, other papers reported the 
possibility to use HDR to correct specific sequences also in the heart of postnatal 
mice (Xie, Zhang et al. 2016, Ishizu, Higo et al. 2017). 
 
2. MATERIALS AND METHODS 
2.1 Cells  
HeLa (cervical epithelial) and U2OS (osteosarcoma) cells were seeded in T75 
flasks (Falcon) and grown in Dulbecco's modified Eagle medium (DMEM) + 
[GlutaMAX-I] + [Pyruvate] 1 g/L D-Glucose (Life Technologies), supplemented 
with 10% Fetal bovine serum (FBS, Life Technologies), 100 U/ml penicillin and 
100 µg/ml streptomycin (Sigma), at 37°C in a humidified 5% CO2 incubator. 
Mouse cardiomyocytes plated in primariaTM (Corining) plates, were kept in 
culture during the experiments in Dulbecco's modified Eagle medium (DMEM) + 
[GlutaMAX-I] + [Pyruvate] 4.5 g/L D-Glucose (Life Technologies) a higher 
Glucose concentration, 20 mg/ml vitamin B12 (Sigma) and 5% FBS. Differently, 
HL-1 cells, an immortalized cardiomyocyte mouse cell line, were grown in 
Claycomb medium (Sigma), supplied with 10% FBS, 100 U/ml penicillin and 100 
µg/ml streptomycin (Sigma) and 2 mM L-Glutamine and kept in culture in 
primariaTM cell culture dish (Corning). Subconfluent cultures of HeLa, U2OS and 
HL-1 were split every 2-3 days using Trypsin. Briefly, the medium was aspirated, 
cells were washed with phosphate-buffered saline (PBS) (KH2PO4 1.8 mmol/L; 




(diluted in PBS) were added to detach cells. After cell detachment, cells were 
resuspended in culture medium and re-seeded for propagation of the cultures 
(typically 1:5 dilution) or for experiments.  
 
2.2 MicroRNA mimics and siRNAs 
MiRNA mimics are small double-stranded RNA sequences, corresponding to the 
same sequences of endogenous human miRNAs. All the miRNA mimics used in 
this project (miRIDIAN miRNA mimics) and siRNAs (siGENOME SMARTpools) 
were purchased from Dharmacon (GE Healthcare). 
 
2.3 MicroRNAs/siRNAs transfection  
Transfection of human miRNA mimics or siRNAs was performed using a 
standard reverse transfection protocol, at a final miRNA/siRNA concentration of 
50 nM. For experiments performed in 96-well plates, 15 μl of 500 nM 
miRNAs/siRNAs were transferred to 96 well plates. Transfection reagent, 
Lipofectamine RNAiMAX Transfection Reagent (0.2 μl per 96-well, Life 
Technologies) diluted in 35 μl of OPTI-MEM (Life Technologies) was then added 
to the miRNAs/siRNAs arrayed on 96-well plates and incubated at RT for 30 min. 
HeLa, U2OS cells, and mouse CMs, suspended in 100 μl antibiotic-free culture 
medium, were then seeded onto the 96-well plates at different densities 
depending on the cell line (HeLa: 8x103 cells per well; U2OS: 6x103 cells per well; 
CMs: 1x104 cells per well) and incubated at 37°C, 5% CO2. For experiments in 
384-well plates, 5 μl of 500 nM miRNA/siRNA were transferred to each well and 
0.1 μl of Lipofectamine RNAiMAX Transfection Reagent (Life Technologies) 
diluted in 15 μl OPTIMEM was added. After 30 min, cells were seeded onto the 
plates at a density of 1.5x103 cells per well and incubated at 37°C, 5% CO2. 
Transfections performed in 6-well plate format were done using the same 
procedure, but transferring 7 ul from the 20 uM miRNAs/siRNAs stock to each 
well. 5.7 ul of Lipofectamine RNAiMAX were diluted in 600 ul of OPTI-MEM and 
then added to miRNAs/siRNAs. 30 min. after, 3x105 cells per well, resuspended in 





2.4 Production, purification and characterization of rAAV vectors 
The AAV Vector Unit (AVU) at ICGEB Trieste (http://www.icgeb.org/avu-core-
facility.html), generated as described previously (see paragraph 1.2.5) all the 
AAV vectors used in this project. Briefly, infectious AAV6 and AAV9 vector 
particles were generated in HEK293T cells by co-transfecting each vector 
plasmid together with the packaging plasmid expressing AAV capsid proteins 
and Adenovirus helper proteins, pDF6 for AAV6 (King, Dubielzig et al. 2001) and 
p5E18-VD2/9 for AAV9 (Inagaki, Fuess et al. 2006). Plasmid p5E18-VD2/9 
(providing AAV2 Rep and AAV9 Cap genes) was provided by Dr James M. 
Wilson. Viral stocks were obtained by CsCl gradient centrifugation; rAAV titers, 
determined by measuring the copy number of viral genomes in pooled, dialyzed 
gradient fractions, were in the range of 1x1012 to 1x1013 genome copies per ml. A 






AAV serotype 6 SgRNA_ES#1 
AAV serotype 6 Myl2_T2A_eGFP 
AAV serotype 9 SgRNA_ES#1 
AAV serotype 9 Myl2_T2A_eGFP 
AAV serotype 9 hsa-miR-302d 
AAV serotype 9 hsa-miR-520c 
 
2.5 The high-throughput screening  
The high content screening was performed in U2OS cells transfected with a 
human microRNA mimics library, composed by 2,042 mature double-stranded 
RNA sequences (miRBASE, version 21.1, October 2018) arrayed in 384 well 
plates. A standard reverse transfection protocol was used to transfect cells with 




triple-plasmid HR detection assay to evaluate HR-mediated GFP correction and 
expression. A final concentration of 36 ng of DNA/well was transfected to cells (5 
ng of pCUB-eGFP-Y66S; 11.5 of px330_SpCas9; 19.5 ng of pGEM T 
easy_delta20GFP*), diluted in 20 ul of OPTiMEM and using FuGENE HD 
(Promega) (with a ratio 3.5 ul FuGENE HD each ug of DNA) as transfection 
reagent. The GFP accumulation was monitored 72 hours after plasmids 
transfection. Cells were then washed twice with PBS, fixed with PFA 4% for 15 
min. at RT, permeabilized with 0.5% Tryton-X diluted in PBS for 10 min., washed 
again with PBS, blocked with 2% BSA diluted in PBS and stained with an Ab 
(ab6556, Abcam) recognizing the total amount of GFP to normalize the results 
over transfection efficiency. The screening was run in duplicate. With this 
unbiased method we identified a list of human miRNAs strongly increasing 
CRISPR/Cas9-based HR, up to 3-fold over control.  
 
2.6 AAV transduction in HL-1 and cardiomyocytes 
Twenty-four hours after miRNA/siRNA transfection, recombinant AAV6 vectors 
coding for the sgRNA and for the template for correction were added to Cas9+ 
mouse cardiomyocytes and HL-1 cells with different ratio between the two 
viruses. Upon transduction condition optimization, the vectors were added to 
cells at specific multiplicities of infection (m.o.i.), corresponding to 10,000 
vgp/cell in total. Ninety-six hours after transduction, the medium was removed, 
cells were washed with PBS and processed for fluorescence imaging.  
 
2.7 Fluorescence Microscopy, image acquisition and analysis 
To prepare the samples for fluorescence imaging, U2OS cells were fixed with 4% 
paraformaldehyde (Hummel, Li et al.) for 15 min. and washed with PBS. Cells 
were then permeabilyzed using 0.5% Tryton X-100 (Sigma), washed once more 
with PBS and blocked with 2% bovine serum albumin (BSA), diluted in PBS. 
After 1 hour, we immunostained cells with an Ab recognizing both folded and 
misfolded eGFP, produced in rabbit (ab6556, Abcam), diluted in blocking 




were able to normalize the data over the transfection efficiency. Cells were then 
washed twice with PBS and a secondary fluorescent (Alexa 594) anti-Rabbit Ab 
(diluted 1:500 in blocking solution) was added to cells and incubated for 2 hours 
at room temperature (RT). After this time, cells were washed again with PBS 
and Hoechst 33342 (diluted 1:5,000, Life Technologies) was used to counterstain 
nuclei. Differently, mCMs, after fixation (PFA 4%, 10 min.), permeabilization 
(0.5% TrionX-100 for 10 min.) and blocking (2% BSA for 1 hour), were stained 
with a combination of two Abtibodies: the first corresponds to the same used to 
stain U2OS cells (ab6556, Abcam), while the second recognizes the sacromeric 
alpha-actinin (produced in Mouse), diluted in blocking solution 1:250 (EA-53, 
Abcam). Plates were kept at 4 °C overnight in darkness. The day after, cells were 
washed twice with PBS and anti-mouse 594 (Invitrogen) and anti-rabbit 488 
(Invitrogen) secondary Ab (diluted 1:500 in blocking solution) were added 
together and incubated for two hours at RT. After this time, cells were washed 
again with PBS and Hoescht (Invitrogen, #33342) was added. The screening high 
content image acquisition was performed using ImageXpress Micro automated 
high-content screening fluorescence microscope (Molecular Devices). Images 
were acquired at 10x magnification to reach approximately 1,500 cells analyzed 
per condition. Image analysis was performed using the “Multi-Wavelength Cell 
Scoring” application module implemented in MetaXpress software (Molecular 
Devices). Whereas, all the experiments not related to the screening plates were 
acquired at 20x magnification with a total of 15 images per well using the 
Operetta high-content imaging system (PerkinElmer) and analyzed with 
Columbus image data storage and analysis platform (PerkinElmer).  
 
2.8 Total RNA extraction from 6-well plates 
Total RNA was extracted from U2OS and cardiomyocytes seeded onto 6-well 
plates by using TRIzol Reagent (Life Technologies) taking care at recovering the 
aqueous phase, without interphase contamination. Cells were lysed in 1 ml of 
TRIzol Reagent per well and homogenate was recovered, put in Pre-spun Phase 




of TRIzol was added and the tubes were shaken vigorously for 15 s. Samples 
were then centrifuged at 12,000 x g for 10 min at 4°C. After the centrifugation, 
the upper aqueous phase, was transferred to a new tube and 1.5 volumes of 
100% ethanol was added. 700 ul of the samples, including any precipitate, were 
transferred into RNAeasy mini spin columns (Qiagen) and centrifuged at 8000 x 
g for 30 s. After this step, the flow-through was discarded, 700 μl of RWT Buffer 
was added to the columns and the tubes were centrifuged for 15 s. at 8000 x g to 
wash the columns. After the washing step, 500 μl of RPE Buffer was added and 
the samples were centrifuged for 15 s. at 8,000 x g. This step was repeated a 
second time by adding 500 μl of RPE Buffer and centrifuging tubes for 2 min. at 
8000 x g. The RNeasy Mini spin columns were placed into a new 2 ml collection 
tube and centrifuged at full speed for 1 min. This additional step was done to 
eliminate any possible carryover of Buffer RPE or other residual. Tubes were 
then left opened under chemical hood to allow the complete evaporation of the 
EtOH and further dry the membrane. Finally RNeasy Mini spin columns were 
transferred to new 1.5 ml collection tubes and 50 μl of RNase-free water were 
added directly onto the RNeasy Mini spin columns and incubated for 2 min.. 
Columns were centrifuged at 8000 x g for 1 min. to elute the RNA. This step was 
repeated twice to improve the RNA concentration. 
 
2.9 Reverse Transcription PCR 
Total RNA concentration was measured using Nanodrop 1000 (Thermo 
Scientific). 1 μg of total RNA was used for cDNA synthesis. The RNA was diluted 
into 11 μl of RNAse-free water and treated with 2 μl of RNAse-free DNAse I 
(Roche), 1.5 μl of Buffer 10x (Roche) and 0.5 μl of PRI (Roche) for 15 min, at RT. 
DNAse I was then inactivated by rising the temperature to 75°C for 5 min. After 
DNAse digestion, RNA was incubated with 2 μl of 10 mM dNTPs (Promega), 2 μl 
of random primers (Invitrogen, 1:20 dilution) and 5 μl of RNAse-free water for 5 
min at 65°C. Reverse transcription was performed by using 8 μl of 5x First-
Strand Buffer (Invitrogen), 4 μl of DTT 0,1 M (Invitrogen) and 2 μl of PRI 




then 2 μl of Maloney murine leukemia virus reverse transcriptase (M-MLV RT, 
Invitrogen) were added. The reverse transcription reaction was performed as 
follows: 10 min at 25°C (RT activation), 50 min at 37°C (RT reaction), 15 min at 
72°C (RT inactivation). 
 
 
2.10 Real-Time PCR 
To measure how different miRNAs affect expression of particular genes, we 
performed Real-Time PCR using the TaqMan assay (Applied Biosystems). 
GAPDH was used as housekeeping gene for normalization. cDNA (1 μl) was 
treated with 10 μl of TaqMan mix (Qiagen – not correct), 8 μl of RNAse-free 
water, 1 μl of the TaqMan probes and analized by using a standard TaqMan 
protocol using a CFX96TM Real-Time System (Bio-Rad) (95°C for 10 min, 
followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min), according to the 
manufacturer's recommendations. TaqMan probes consist of a fluorophore (R) 
covalently bind to the 5'-terminus of an oligonucleotide probe and a quencher 
(Q) on the 3'-terminus. 
In the beginning, quencher and reporter are very close and Q quenches the 
fluorescence emitted by R, when exited by a specific wavelength. During the 
annealing, TaqMan probes bind to the target sequence. Then, during the 
elongation phase, the Probe is partially displaced, the reporter is cleaved and 
becomes able to produce fluorescence. The resulting fluorescence is 
proportional to the quantity of amplified product in the samples. A list of the 
used probes is summarized in the tab. 2 and 3. 
 
Tab. 2 
TARGET Probe ID 
hsa-MRE11 Hs00967437_m1 
hsa -NBN Hs01039834_m1 
hsa -RAD50 Hs00990023_m1 




hsa -MAPK11 Hs00177101_m1 
Tab. 3 





2.11 Total RNA extraction from Heart sections  
Heart sections of treated animals were lysate with TRYzol (Invitrogen) and 
dissociated using MagNA Lyser green beads (Roche) at 6500 rpm for 60 
seconds. After this, the homogenate was put in 1.5 ml tubes and incubated for 5 
min at RT. 0.2 ml of chloroform per ml of TRIzol were added and the tubes were 
shaken vigorously for 15 s. Samples were then centrifuged at 12,000 x g for 10 
min at 4°C. Total RNA was extracted using NucleoSpin miRNA kit (Machery-
Nagel), according with manufacture’s instruction. 
 
2.12 miRCURY miRNAs quantification  
To determine the miRNAs expression in the extracted hearts we used the 
miRCURY LNATM Universal RT microRNA PCR (EXIQON). Total RNA was 
extracted (as described 9n the section 2.11) and then diluted to a final 
concentration of 5 ng/ul using nuclease free water. Reverse transcription 
reaction was prepared by using 2 ul of diluted RNA, according with 
manufacture’s instructions and following the subsequent PCR conditions: 60 
min. at 42°C; 5 min. at 95°C; immediately at 4°C. The deriving cDNA was then 
diluted 1:80 in nuclease-free water. Real-Time reaction was prepared according 
with manufacture’s instructions and using the primers listed in the Tab. 4 to 
detect hsa-miR-520c-3p and hsa-miR-302d-3p. As internal control we used the 
U6 small nuclear RNA, stably expressed in the tissue.  
 
Tab. 4 










2.13 Cell cycle profile evaluation  
U2OS cells were seeded in 6-well plate and reverse transfected with hsa-miR-
520c-3p, hsa-miR-302d-3p, hsa-miR-4469 and mimic#4. 72 hours after 
transfection, 1X Trypsin was used to detach the cells and centrifuged at 1300 
rpm for 1 min. The pellet was then resuspended and washed twice with PBS and 
the surnatant was removed.  Upon the washing step, cells were resuspended in 1 
ml of 50 mg/ml propidium iodide (PI) (Sigma #P4864) solution diluted in water 
and supplied with 0.1% Na3C6H5O7, 0.1% NP40 and 12.5 ul of 0.5mg/ml RNAse, 
DNAse free (Roche, #11119915001). Cells were incubated for 20 min. at RT in the 
darkness. Cytofluorimetric analysis was performed by considering a population 
of 10,000 cells for each sample. 
 
2.14 Western-Blot quantification  
Protein expression was evaluated by western-blot quantification: treated cells 
were washed in ice-cold PBS and Proteins were harvested in RIPA lysis buffer (20 
mM TrisHCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5 % sodium deoxycholate, 0.5 
% NP40, 0.1 % phosphatase inhibitors (Sigma P0044), 1 % PMSF, EDTA free 
proteinase inhibitor tablet (Sigma 04693159001) (1 tablet/10 ml buffer)). Cell 
lysates were then sonicated with Bioruptor (Diagenode) for 30 minutes using 3 
pulses of 10 minutes each. After this, samples were then centrifuged at 13,000 
rpm for 20 min. at 4°C, the surnatants were collected and protein concentrations 
were quantified by Bradford colorimetric assay (BioRad, CA, USA). Samples 
were resuspended with Laemmli sample buffer (30% glycerol, 3% SDS, 0.19 M 
Tris HCl, pH 6.8, 0.015% bromophenol blue, 3% 2-mercaptoethanol), denatured 
by boiling for 5 min at 90 °C and resolved by SDS-PAGE of the relevant 




transferred to a nitrocellulose membrane (GE Healthcare, 10600015), at 350 mA 
for 1 hour at 4°C. After this step, membranes were blocked for 1 hour at RT using 
5% milk or 5% BSA, diluted in TBS-T (0.1% Tween20). Primary Abs were diluted 
in blocking buffer, added to membranes and incubated overnight at 4°C. Blots 
were then incubated with HRP conjugated secondary Abs (see tab. 5) for 1 hour 
at RT. GAPDH was used as standard control through all the experiments. Band 
intensity was analyzed using ImageJ software. In the tab. 5 are listed the Ab 





Tab. 5  
PRIMARY Antibodies 
TARGET COMPANY CODE SPECIES 
CHK-2 Cell Signaling, BK2662S Rabbit 
P-CHK-2 Novus Biologicals, NB-100 
92502 
Rabbit 
H2AX(ser139) Millipore, 05-636 Mouse 
MRE11 Santa Cruz, sc-5859 Rabbit 






RAD50 Novus Biologicals, NB110-
60438 
Rabbit 
RAD51 Santa Cruz, sc-8349 Rabbit 
P38α/β Cell Signaling, 9212 Rabbit 
P-P38 Cell Signaling, 9211 Rabbit 
GAPDH Santa Cruz, sc-25778 Rabbit 










HRP-Anti-Rat DAKO, P0450 Rabbit 
  
2.15 Deep-sequencing analysis 
The RNA-seq analysis was performed in collaboration with Macrogen Inc. 
(Seoul, Korea). After total RNA extraction from un-transfected samples or 
samples treated with the negative control (mimic#4) or with the selected 
miRNAs, the company provided us the subsequent specification for RNA 




stranded, polyA enrichment); Illumina NovaSeq 2x100bp sequencing (library 
run, 30 million reads per sample). The transcriptomic analysis was run in 
triplicate and data analysis was performed in collaboration with Danilo Licastro 
from “Consorzio per il centro di Biomedicine Molecolare” (CBM), AREA science 
park, Basovizza, Trieste.  
 
2.16 T7 endonuclease Assay  
The T7E1 assay was performed following the manufacturer’s instructions 
(M0302, New England Biolabs, MA, United States). 100 ng of genomic DNA 
(extracted from cells treated with plasmids expressing Cas9 and the different 
sgRNAs or transfected only with Cas9 coding plasmid) were used to amplify the 
target region. The PCR reactions were conducted, using the oligonucleotides 
(Sigma-Aldrich) listed in Tab. 6, according to the protocol of the Taq polymerase 
used (Roche). The PCR program was optimized with the following cycles: 1 cycle 
of 2 minutes at 94°C; 35 cycles of 30 seconds at 94°C, 45 seconds at 58°C and 1 
minute at 72°C; 1 cycle of 7 minutes at 72°C. The PCR amplicons were purified 
using Wizard SV Gel and PCR Clean-Up System (Promega) following the 
manufacturer’s instructions. 500 ng of purified amplicons were heat denatured 
and slowly re-annealed to facilitate heteroduplex formation between the WT 
and the cleaved sequence by using optimized PCR conditions: 5 min. at 95°C; 3 
min. at 90°C; 3 min at 65°C; 3 min at 63°C; 3 min at 37°C and 10 min at 25°C. The 
eteroduplex, diluted in 1X NEB2 Buffer, were then digested with the T7E1 
enzyme (New England Biolabs, NEB) at the mismatch locus for 60 min. at 37°C. 
After this step, samples were loaded in a polyacrylamide gel to separate the 
resulting digested bands, using 100 bp DNA ladder (Promega) as referring 
marker. To evaluate the separation the gel was soaked in diluted Ethidium 





Tab. 6  
T7 endonuclease Primers Sequences 
My2_Exon7_Fw Primer CTCTTGCTTGCAGATCGACC 
My2_Exon7_Rev Primer GGCAGGTGGATCTCTGAGTT 
 
2.17 3’UTR-Luciferase Assay  
In order to determine possible targeting of miRNA-4469 to the 3’UTR of 
MAPK11, a portion of the 3’UTR sequence was purchased from GenScript and 
cloned into the reporter vector psiCheck2 (Promega) using the restriction 
enzyme PmeI and NotI (New England Biolabs). HeLa cells were reverse 
transfected on day 0 in a 96 well comparing UNTR_LIPO with the selected 
miRNAs. After 24h cells were transfected with empty psiCheck2 vector of the 
vector containing the MAPK11 3’UTR sequence. After additional 48 hours cells 
were washed with PBS, harvested in 60 ul GloLysis Buffer (Promega) and 
assayed using the DualGlo Luciferase kit (Promega). Renilla luminescence was 
normalized over firefly luminescence. In addition, to account for the effect of the 
miRNAs on plasmid transfection, an additional normalization step was carried 
out by dividing the psiCheck2-3’UTR measurements by the corresponding 
empty vector measurements for each miRNA treatment. 
 
2.18 Mouse cardiomyocyte preparation  
Ventricular CMs were isolated from both male and female neonatal mice. 
Briefly, ventricles from neonatal (P0) mice were cut into pieces inside a 2.6 cm 
petri dish filled with and ice-cold calcium and bicarbonate-free Hanks with 
HEPES (CBFHH) buffer. Upon cutting the hearts in pieces, the fragments were 
transferred in a falcon, resuspended in an appropriate volume of Trypsin and 
dissociated using mechanical and physical stirring. Digestion was then 
performed at 37°C in 4-min steps for 6-8 times with collection of the supernatant 
to ice-cold fetal bovine serum (FBS, Life Technologies) after each step. The 
collected supernatant was passed through a cell strainer (40 mm, BD Falcon) 




modified Eagle medium 4.5 g/l glucose (DMEM, Life Technologies) 
supplemented with 5% FBS, 20 mg/ml vitamin B12 (Sigma) and 100 U/ml 
penicillin and 100 mg/ml streptomycin (Sigma). After centrifugation, cells were 
then seeded onto 100-mm plastic dishes for 3 hours at 37°C in 5% CO2 and 
humidified atmosphere to allow fibroblast attachment to the dish surface. After 
this time, the supernatant, composed mostly of CMs, was then collected, cells 
were counted and plated at the appropriate density into collagen-coated ULTRA 
Primaria 96-well plates (PerkinElmer).  
 
2.19 Mice injection, hearts extraction and slices preparation 
All the animals were housed with optimal environmental conditions. All animal 
experiments followed the European guidelines and international laws and 
policies (ECC Council Directive 87/609, OJL 348, 12 December 1987) with the 
approval of the ICGEB Animal Welfare Board, the Italian Minister of Health and 
the Ethical Committee.  
Neonatal P1 Cas9+ mice were intraperitoneally injected twice in a day using 
Micro-FineTM 0.3 ml syringes (30G) (Jansen, Embden et al.). Animals were 
therefore treated firstly in the morning with 30 ul of high titers of AAV9 coding 
for hsa-miR-520c-3p and hsa-miR-302d-3p (4x1011 vgp/mouse) and secondly, in 
the evening, they were injected with 30 ul of the combination of AAV9 coding 
for the guide and the template for eGFP HR-mediated insertion (2.5x1011/mouse 
for each virus). After one month, animals were sacrificed, the hearts were 
perfused using PBS to allow a complete washout of the remaining blood, 
extracted and immediately cut on the longitudinal direction. Half of the heart 
was fixed overnight at 4°C using PFA 4% and processed for fluorescence 
microscopy, while the other half was use for RNA extraction in order to quantify 






3.1 High content screening to identify human microRNAs affecting CRISPR-
Cas9-based homologous recombination 
Genome editing based on homologous recombination (HR) (Thomas and 
Capecchi 1987), is the gold standard treatment for gene therapy of inherited 
mutations. However, this process is based on a very rare event, in particular in 
post-mitotic cells and tissues, such as neurons or cardiomyocytes. The advent of 
the CRISPR-Cas9 technology has dramatically changed the perspectives in this 
field, allowing researchers to introduce specific double stranded cuts in the 
genome to boost HR. Nevertheless, this tool is not yet optimized for clinical 
applications and there is a strong need to find strategies to improve the 
efficiency of HR-based gene correction. 
To identify possible factors able to improve the efficiency of CRISPR-Cas9-based 
HR, we optimized a robotized high content screening approach to study these 
events. Since HR is a very sporadic and complex biological process, we decided 
to investigate the possibility to improve its efficiency using endogenous, multi-
target molecules, such as human microRNAs, given the property of these 
molecules of targeting multiple genes at the same time and their involvement in 
numerous biological processes, as outlined in the Introduction.  
To optimize the possibility to identify a detectable number of events in a high-
content setup, we designed a transient HR recognition assay. For this purpose, 
we transfected the human U2OS osteosarcoma cell line with a combination of 
three plasmids: an HR reporter, a DNA template for correction and a CRISPR-
Cas9 coding plasmid also containing information for a single-guide RNA 
sequence (figure 10 panel A). As an HR reporter we took advantage from an 
already published plasmid, pCUB-eGFP-Y66S (Tran, Liu et al. 2003). This codes 
for an eGFP sequence carrying a single point mutation (A to C) at position 201 of 
the EGFP gene, resulting in Tyr66 to Ser66 amino acid conversion 
(pUC_eGFP_Y66S). This mutation allows the production of an improperly folded 
eGFP and completely abrogates its fluorescence. The homologous template for 




corresponds to a truncated eGFP sequence lacking the ATG and the last 20 
nucleotides and carrying a silent point mutation inside the PAM region, in order 
to avoid Cas9 recognition after gene correction. A third plasmid codes for the 
humanized sequence of the Streptococcus pyogenes Cas9 and for the single 
guide RNA (gRNA-eGFP5) targeting the eGFP sequence and driving the 
nuclease specificity. Cas9 and sgRNA expression are driven by the constitutive 
CMV and the human U6 RNA promoters, respectively. 
By co-transfecting these plasmids into U2OS cells, we could visualize the 
appearance of green fluorescent cell clusters exclusively in the samples treated 
with the complete combination of the three plasmids (figure 10, panel B). After 
fixation, we stained the cells with an antibody recognizing both the folded and 
the unfolded eGFP proteins, in order to normalize the data for transfection 
efficiency. Representative images in figure 10 panel C show the green GFP+ cells 
corresponding to successful gene targeting events, and the total transfected 







Figure 10: (A) The HR detection assay consists of a triple plasmid transfection 
protocol in U2OS cells: the first plasmid codes for the HR reporter, a mutated eGFP 
sequence, point-mutated in lysine 201, which creates a misfolded non-fluorescent 
protein; the second plasmid is the template for correction (a truncated eGFP 
sequence carrying a silent point-mutation in the PAM recognition site); the third 
plasmid codes for the humanized version of the Streptococcus Pyogenes Cas9, 
together with a guide RNA targeting the eGFP DNA sequence (SgEGFP5). (B) Basal 
level of HR detection in samples co-transfected with the complete combination of 
the three plasmids. (C) Schematic summary of images acquisition and 
representative images of cells in which recombination had occurred. GFP+ cells 
correspond to HR events; the red cells (stained with an Alexa594-labeled antibody 
against both folded and unfolded GFP) permits visualization of transfection 






3.2 High-throughput screening protocol and image processing  
Once we set up the experimental conditions for the HR assay, we proceeded 
with the high-throughput screening. For this purpose, we plated and reverse 
transfected U2OS cells with a genome wide library of 2,042 human miRNAs 
(human miRNA mimic library, miRBASe version 19) arrayed in a 384-well plate 
format. After 24 hrs, we transfected the three plasmids of our assay and, after 
additional 72 hours, we fixed the cells and immunostained them for total eGFP 
expression in order to quantify transfection efficiency. We acquired a total of 4 




As negative controls in our screening, we used two miRNA mimics (mimic#1 – 
cel-miR-67 and mimic#4 – cel-miR-231) derived from from C. elegans, selected 
for the absence of any homology with human miRNAs and known to not induce 
any toxicity. As an additional control, we also included treatment with a siRNA 
against Ubiquitin C (UBC), a component of the proteasome-ubiquitin system 
that is essential for cell survival, the silencing of which leads to cell death. The 
use of this siRNA allows an easy evaluation of transfection efficiency, by simply 
counting the number of surviving cells. 
 
3.3 The identification of human microRNAs able to positively modulate 
homologous recombination pathway  
Using this unbiased approach, we identified a number of human microRNAs that 
are able to positively modulate HR frequency. The graph in the figure 12, panel A 
shows the distribution of the miRNAs exerting positive and negative effect on 
HR. The screening was performed in duplicate and the comparison of the results 
showed good reproducibility (P value = 0.10) (Figure 12, panel A). We identified 
50 miRNAs positively affecting efficiency of HR by more than 2 fold (figure 12, 
panel B) and 20 miRNAs that significantly improved HR events up to 3-fold over 
mock treated control (UNTR_LIPO), without affecting plasmid transfection or 
cell viability.  
Representative images in figure 12, panel C show the effect of six selected 
miRNAs, miR-302a-3p, miR-302d-3p, miR-520b, miR-520c-3p, miR-520e and 
miR-520f, which all increased the number of GFP-positive cell clusters, and 
indication of successful gene targeting events. 
  
Figure 11: We arrayed the 2,042 human microRNA mimics in 384-well plate format 
and plated U2OS cells in each well to achieve reverse-transfection. At 24 hours after 
transfection we added the 3 plasmids of the assyas and, 72 hours later, we fixed the 
cells and stained them with an Ab recognizing transfected eGFP (Alexa 594). The 






78 We focused on the top 20 miRNA hits of our screening for further analysis.  
Figure 12: (A) The comparison between the two replicates of the screening resulted 
statistically significant (pvalue < 0.10) and reported a list of 50 miRNAs as positive 
modulators of HR up to 3-fold over UNTR_LIPO. (B) An overview of the results 
underlined how miRNAs both positively and negatively influence Cas9-mediated 





First, we re-tested their ability to increase HR efficiency in U2OS cells using the 
recombination assay described above.  As shown in figure 13, panel A, for all 
these miRNAs we could confirm the induction of GFP-positive, recombinant 






Figure 13: The graph in panel A corresponds to the validation of the miRNAs 
selected from the screening while panel B shows the effect of HR improvement in 
genome-integrated targets. Data are mean ± SEM (N = 3 individual experiments); *p 
< 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA. The 8 miRNAs that belong to 
cluster 520 are marked in red, while the 2 from cluster 302, are in blue. The miRNAs 
in white are not included in the two clusters, while in green are the controls. In both 
graphs, the selected miRNAs used for further experiments are marked with striped 
columns. Panel C shows the conserved seed sequence shared by the hits of the 
screening that belong to the enriched clusters. The seed sequence of miR-4469 is 





Interestingly, an accurate analysis of these miRNAs revealed that 10 out of the 
top 20 molecules belong to two enriched miRNA clusters (miR-520 and miR-302, 
figure 13, panel C) known to be overexpressed in embryonic and pluripotent 
stem cells (Ren, Jin et al. 2009) and almost absent in post-mitotic cells. The 
miRNAs belonging to the same cluster share the same seed sequence 
(AAGUGC), which most likely indicates a similar gene regulation profile and a 
common mechanism of action. Therefore, these miRNAs possibly lead to the 
improvement of HR frequency by modulating conserved pathways and gene 
networks. 
In order to evaluate the effect of the top selected miRNAs hits on a genome-
integrated target, we generated a stable cell line, carrying the eGFP-Y66S 
reporter sequence stably integrated into the AAVS1 locus of U2OS cells. Using 
these cells, we screened the top 20 miRNAs for their ability to induce 
recombination events and the appearance of GFP+ cells. Twenty-four hours 
after miRNAs treatment, we co-transfected cells with the template and the 
SpCas9 expressing plasmids and incubated them at 37°C for further 72 h. In this 
experimental setting, we obtained a different ranking of efficacy of the 20 
different miRNAs, with miR-4469 resulting the most efficient at inducing HR 
events (figure 13 panel B). This miRNA has a different seed sequence (CUCCCU) 
compared to the miR-302 and miR-520 clusters (figure 13, panel B), meaning 
that its effect on HR is probably mediated by a different gene modification 
profile. Taken together the results of the validation experiments, we decided to 
concentrate our study on three molecules, hsa-miR-4469 plus two 
representatives of the miRNA clusters (hsa-miR-520c-3p and hsa-miR-302d-3p) 
figure 13 panels A and B (striped marked columns).  
 
3.4 Evaluation of the effect of the selected miRNAs on the modulation of the 
non homologous end joining DNA repair pathway  
Since HR is one of the two possible DNA repair mechanisms and mammalian 
cells preferentially use NHEJ to resolve DNA double strand breaks, we wanted to 




pathway or also extends to NHEJ. We evaluated the possible effect of the 
miRNAs on activation of the NHEJ pathway by taking advantage of a reporter 
plasmid designed to identify all the possible classes of NHEJ events (Bennardo, 
Cheng et al. 2008). This plasmid contains a promoter and a GFP sequence that 




two I-Sce-I recognition sites that are in the same orientation (figure 14, panel A). 
When the reporter plasmid is co-trasfected in U2OS cells together with an I-Sce-
I expression plasmid, the I-Sce-I enzyme cuts at the corresponding recognition 
sites eliminating the Puro sequence. Then, the two staggered end generated by 
the cut are repaired by NHEJ reconstituting the GFP expression cassette.  
In cotransfection experiments, among the 20 different miRNAs tested, only 
miR-143 showed a significant improvement in the number of GFP+ cells (up to 2-
fold over UNTR_LIPO), while all the other miRNAs were ineffective at 
stimulating the NHEJ-mediated DNA repair, underling their specific effect on 
HR. 
 
3.5 The selected microRNAs modify the cell cycle profile 
To start understanding the mechanisms of HR enhancement and since it is 
known from literature that the HR events occur in the S and G2/M phases of the 
cell cycle (Aylon, Liefshitz et al. 2004, Ira, Pellicioli et al. 2004), we decided to 
evaluate the cell cycle profile of U2OS cells after treatment with the selected 
miRNAs. In this experimental setup we used as negative control mimic#4 
(previously used in the screening) and compared the possible cell cycle 
modifications induced by the 3 selected miRNAs (hsa-miR-302d-3p, hsa-miR-
520c-3p and hsa-miR-4469) to the effect of UNTR_LIPO.  
At 72 h after miRNA transfection, we collected the cells for propidium iodide (PI) 
staining and FACS analysis to evaluate the different cell cycle profiles (figure 15 
panel A). The results of these experiments confirmed a significant reduction of 
cells in G1 (from 59% to 45-47%) together with a consequent accumulation in S 
Figure 14: (A) Schematic representation of EJ5-GFP reporter plasmid. The reporter 
corresponds to a WT eGFP sequence separated from its promoter by a puromycin 
resistance cassette flanked by two I-SceI recognition sites. By co-transfecting this 
construct together with the I-SceI expression plasmid, the puromycin cassette is 
excised and the GFP gene is expressed due to the cut followed by NHEJ-mediated 
DNA repair. Data are mean ± SEM (N = 3 individual experiments); *p < 0.05; one-
way ANOVA. (B) Effect of the selected miRNAs on NHEJ. (C) Representative images 





and G2/M (from 20% to 28-29%) (figure 15, panel B) upon treatment wih the 
pro-recombinogenic miRNAs. Interestingly, while this cell cycle alteration 
resulted evident in all the miRNA-treated samples, the S-G2/M shift was more 
evident in the samples treated with hsa-miR-520c-3p and hsa-miR-302d-3p 








Figure 15: (A) Results of the cell cycle profile analysis of U2OS cells un-transfected 
and transfected with the negative control (mimic#4) or with the selected miRNAs 
(hsa-miR-520c-3p; hsa-miR-302d-3p; hsa-miR-4469). (B) The graph shows the 






3.6 The selected molecules do not induce DNA damage and upregulate key 
components of homologous recombination machinery 
 Cellular DNA damage response (DDR) and repair mechanisms are triggered by 
stimuli that threaten DNA integrity. For this reason, to evaluate whether the 
miRNA treatment might induced by itself DNA damage, we performed a 
comprehensive survey of activation/expression of DNA damage markers in cells 
treated with the selected miRNAs. By western-blot analysis, using protein 
extracts from treated U2OS cells, we evaluated the activation and accumulation 
of Chk2, P-Chk2 and γ-H2AX proteins. The carboxy-terminal phosphorylation of 
H2AX is one of the earliest DNA damage responses of DSB formation 
(Fillingham, Keogh et al. 2006). As a positive control for DNA damage 
activation, we used UV treated U2OS cells (at a fluence of 20 J/m2) (Hanasoge 
and Ljungman 2007).  
The results of these western blots did not show any DNA damage marker 
activation in the miRNA-treated samples, in comparison with the UV positive 
control, in which the levels of both P-Chk2 and γ-H2AX increased (figure 16, 
panel A). 
We then decided to evaluate the effect of the selected miRNAs on well-
described components of the HR pathway. Upon DNA DSB formation, one of 
the first DNA repair steps is the recognition of the broken DNA ends by the MRN 
complex (Zha, Boboila et al. 2009, Taylor, Cecillon et al. 2010), composed by 
three key proteins: MRE11, NBS and RAD50. Once this occurs, another HR-
associated protein, replication protein A (Ward, Norat et al.), accumulates in the 
region (Chen and Wold 2014). Then, this is rapidly replaced, through the activity 
of RAD52, by the most important component of the HR pathway, the ATP-
dependent recombinase RAD51 (Bianco, Tracy et al. 1998). For these reasons, 
we decided to evaluate possible variations in gene expression and protein 
accumulation of the three MRN components and the ATP-dependent 
recombinase RAD51. Western blot analysis showed an accumulation of the three 
MRN proteins in both hsa-miR-520c-3p- and hsa-miR-302d-3p-treated samples 




significant RAD51 protein enrichment. A similar scenario was also confirmed by 
checking the mRNA levels of these proteins by Real Time PCR of cells in which 
we transfected the selected miRNAs, after normalization of the results over the 
same controls (figure 16, panel C). Therefore, despite the absence of DNA 
damage induction, these miRNAs contribute to upregulate the transcription and 
activation of components of the HR machinery. In contrast, and interestingly, 




underlying that this miRNA affects HR through different pathways.  
3.7 Analysis of the transcriptome in cells transfected with hsa-miR-520c-3p, 
hsa-miR-302d-3p and has-miR-4469 
Trying to better understand the mechanism of action of the three selected 
miRNAs, we transfected U2OS cells with hsa-miR-520c-3p, hsa-miR-302d-3p 
and hsa-miR-4469 and, 72 hours after the transfection, we extracted total RNA 
and performed deep sequencing analysis (the sequencing was performed in 
collaboration with Macrogen, while data analysis was completed by Danilo 
Licastro from CBM, AREA science Park, Trieste). As expected, the results 
highlighted a high correlation between hsa-miR-520c-3p and hsa-miR-302d-3p 
transcriptomic profiles (figure 17 panel A), which was not detected by comparing 
the results obtained from hsa-miR-4469-transfected cells. On these data, 
bioinformatics analysis were performed by focusing on the most enriched and 
downregulated genes. The total gene modulation induced by each single 
treatment is summarized in the Heatmap in figure 17, panel B.  
The results of this unbiased analysis highlighted the enrichment of key gene 
networks correlated with DNA repair and recombination. Moreover, accordingly 
with our previous experiments, we also confirmed how the miRNAs positively 
affected many HR-related genes, among which, RAD51 and the MRN complex 
(figure 17, panel C). Interestingly, we confirmed G1-related cyclins (CCND2) and 
CDKs (CDKN1A) as down regulated in this context. Furthermore, between the 
genes down regulated by hsa-miR-4469, we recognized MAPK11 (p38β), whose 
pathway alteration, together with that of the other MAPKs (ERK and JNK), is 
known to play a role in the HR-mediated DNA repair process (Golding, 
Rosenberg et al. 2007).  
  
Figure 16: (A) Wester-Blot analysis and quantification (B) of un-transfected U2OS 
compared with U2OS transfected with mimic#4 or the miRNA hits to detect the 
activation of the DNA damage response and the accumulation of the HR related 
proteins (MRE11, NBN, RAD50 and RAD51). (C) Results deriving from real time 
quantification of MRE11, NBN, RAD50 and RAD51 mRNA expression in un-
transfected and miRNAs treated cells. Data are mean ± SEM (N = 3 individual 













3.8 MAPK11 (p38β), a possible hsa-miR-4469 target  
Trying to understand the mechanism of action of miR-4469, we concentrated on 
the analysis of its transcriptomic profile. As previously mentioned, in the list of 
the down regulated genes we detected p38β (MAPK11) as a possible direct 
miRNA target. A previously published work (Golding, Rosenberg et al. 2007) 
recognized the signaling from the mitogen-activated protein kinases ERK, JNK 
and p38, as a possible regulator of HR. In particular, these investigators reported 
that, among the other MAPKs, p38β inhibition enhanced HR up to 2-folds over 
control. Therefore, we speculated on the possibility to correlate p38β inhibition 
with the effects of miR-4469 treatment described above.  For this purpose, we 
first confirmed the specificity of miR-4469 in targeting MAPK11; both Real Time 
(figure 18, panel A) and western blot (figure 18, panel B) quantifications 
highlighted a significant reduction of MAPK11, at both the RNA and protein 
levels, only in miR-4469-treated samples. Furthermore, the predicted seed 
sequence of miR-4469 (according to TargetScan 7.2) exactly matches a 
corresponding sequence in two positions of the 3’UTR of the human gene (figure 
18, panel C). Finally, we obtained functional evidence that MAPK11 is a direct 
target of miR-4469 using a 3’ UTR-luciferase assay performed in HeLa cells. 
More specifically, transfection of a luciferase reporter plasmid (psiCheck2, from 
Promega) containing the human 3’UTR sequence of MAPK11 gene cloned at 3’ 
end of the luciferase coding sequence, induced a large and statistically 
significant downregulation of luciferase activity in samples co-transfected with 
miR-4469 (figure 18, panel D). All together these data suggest that miR-4469 
directly regulates p38β. 
Figure 17: (A) Comparison between the gene modulation profile of U2OS cells 
treated with hsa-miR-520c-3p, hsa-miR-302d-3p and hsa-miR-4469. (B) Heatmap of 
the single gene modulation for each treatment. (C) The graphs show the up-







  Figure 18: (A) Gene expression profile of miR-4469 treated U2OS cells. (B) Western 
Blot quantification of MAPK11 and P-MAPK11 total protein samples deriving from 
U2OS cells treated with the selected miRNAs. (C) MiR-4469 seed sequence 
matching with the human MAPK11 3’-UTR. (D) 3’-UTR luciferase assay performed in 
HeLa cells with or without the selected miRNAs overexpression. Data are mean ± 





3.9 Evaluation of homologous recombination modulation by specific 
MAPK11 inhibition 
Starting from these observations, we decided to evaluate the effect of p38β 
inhibition on HR-mediated DNA repair by using the same assay used for the 
screening. First, we tested different concentrations of two well-described highly 
specific p38 chemical inhibitors (SB203580 and ARRY757) to detect a possible 
improvement on the frequency of HR events. The results obtained (data not 
shown) indicated that the inhibitor SB203580, at the concentration of 10 µM, 
was the most effective at improving the HR frequency in these experimental 
settings and therefore it was used in all the subsequent tests.  
To evaluate possible synergistic effects of the MAPK inhibitor and the miRNA, 
we reverse transfected U2OS with miRNA-4469 and, 24 hours later, we added 
SB203580 (10 µM) and transfected cells with our triple plasmids for the HR assay 
(figure 19, panel B). The results of this experiment confirmed the effect of miR-
4469 and also showed that MAPK11 inhibition per se were very efficient at 
improving HR frequency (up to 5-fold over control). The combined treatment 
with SB203580 and miR-4469 further improved the number of HR events, up to 
7-fold over control (figure 19, panel B).  
Figure 19: (A) Representative images of U2OS cells transfected with the HR 
detection system with or without both the miR-4469 and the p38 beta chemical 
inhibitor (SB203580). (B) The graph reports the percentage of recombination 
reached by co-treating cells with the chemical alone or in combination with miR-
4469 (up to 5-fold over UNTR_LIPO). Data are mean ± SEM (N = 3 individual 





These observations confirmed the important role of p38β inhibition in enhancing 
recombination efficiency, but also emphasized the additive role of miR-4469, 
possibly due to the modulation of other associated pathways.   
These observations confirmed the critical role of p38β inhibition at enhancing 
recombination efficiency, but emphasized also the additive role of miR-4469, 
probably due to the modulation of other associated pathways.   
 
3.10 A strategy to investigate homologous recombination and the effect of 
the selected microRNAs in mouse CMs in vitro  
Since in all the previous experiments we used highly proliferating cells, where 
the HR machinery is still active, we decided to test the action of our miRNA hits 
in primary cells, specifically in neonatal cardiomyocytes (CMs) characterized by 
limited in vitro replication potential. 
First, we decided to find a possible detection system to evaluate the number of 
recombination events also in these cells. With this aim, we took inspiration from 
a previously published paper (Ishizu, Higo et al. 2017) and designed an AAV-
based HR assay that allows the in-frame insertion of a promoterless GFP 
cassette into a cardiac-specific expressing gene. As a target locus we used the 
Myosin light chain 2 (Myl2) sequence. 
Using Benchling (https://www.benchling.com/crispr/), an access-free CRISPR 
guide design software, we designed two sgRNAs targeting the terminal part of 
the Myl2 coding sequence. Then, we generated a template DNA, which 
corresponds to a promoterless WT eGFP sequence, in frame with a self cleaving 
peptide sequence (T2A), flanked by two homologous arms (HA) and matching 
with part of the Myl2 locus (figure 20, panel A). The presence of the T2A peptide 
inside the template ensures the production of two separated proteins that fold 
independently. We evaluated the efficiency of the two sgRNAs driving Cas9 
activity using the T7 endonuclease assay after transfection into an immortalized 
mouse muscle-like cell line (HL-1) with or without Cas9 (figure 20, panel B). Both 




selected the sgRNA_ES#1 (TGGGATGGAGAGTGGGCTGT), which scored the 
best in Benchling, to be used in further experiments. 
Next we subcloned the guide and the template in an AAV backbone (pAAV 
adapted). These vectors were used to produce AAV6 particles, a serotype known 
to efficiently transduce CMs in vitro (figure 20, panel C). By transducing mouse 
CMs with the complete AAV6 vector combination, we predicted that, upon HR, 
the eGFP sequence would be inserted in frame into the end of the last exon of 
Myl2 locus. As a consequence, the eGFP expression cassette becomes under the 
transcriptional control of Myl2 promoter and is expressed only in recombined 
CMs. We decided to use Cas9-heart specific expressing mice to optimize the 
probability to detect efficient HR in these conditions (Carroll, Makarewich et al. 
2016).   
We started by reverse transfecting neonatal Cas9 mouse CMs with the selected 
miRNAs and, the day after, we transduced them with the AAV6 HR-cocktail with 
a total m.o.i. of 1x104 vgp/CM. At 72 hours after infection, we fixed the cells and 
performed immunostaining against GFP and alpha-actinin, the latter antibody 
to selectively identify CMs. The results of these experiments confirmed that all 
the three selected miRNAs uperegulated the HR event, as shown by an 
increased number of recombined cells up to 3-fold over UNTR_LIPO (P<0.05; 




Figure 20: (A) Scheme of sgRNA and template DNA designing. The guide RNA 
(Sg_ES#1) targets the terminal part of the Myl2 locus, a cardiac specific gene. The 
template corresponds to a promoterless WT eGFP sequence in frame with the self-
cleaving peptide (T2A), flanked by two homologous arms of 800 bp each. (B) T7-
assay performed in HL-1 cells to evaluate the driving activity of the guideRNAs at 
inducing DNA cleavage in Myl2 locus. (C) Scheme of high-titer AAV6 particles 
production. (D) Evaluation of the effect of the selected miRNAs at improving HR-
mediated eGFP insertion in mouse neonatal Cas9+ CMs. Data are mean ± SEM (N = 









3.11 In vivo evaluation of the effect of the selected microRNAs on Cas9-
based homologous recombination 
Moving from in vitro to in vivo experiments, we used the same constructs to 
produce AAV serotype 9 particles (known to effectively transduce the cardiac 
tissue when injected, either systemically or intracardiacally, in mice) coding for 
the guide and the template. Moreover, we also produced AAV9 vectors 
expressing hsa-miR-520c or hsa-miR-302d (figure 21, panel A). With these tools, 
we decided to evaluate the effect of the AAV-mediated miRNAs overexpression 
on the Cas9-based insertion of the eGFP cassette into the Myl2 locus in vivo.  
We injected intraperitoneally twice in a day the combination of high titer (3x1011 
vgp each virus) AAV9 vectors coding for the HR-cocktail in P1 Cas9+ mice with 
or without the miRNAs coding vectors (n=3). We performed the first injection in 
the morning, giving to Cas9+ mice a high dose (1x1012 vgp/mouse) of AAV9 
coding for hsa-miR-520c, hsa-miR-302d or an empty MCS vecto (AAV-Control). 
The second injection was performed in the evening of the same day. After one 
month, we sacrificed the animals, extracted the hearts, fixed them in PFA 4% 
and processed for microscopic analysis. In order to visualize the GFP fluorescent 
signal and to overcome possible fixation quenching artifacts, we immunostained 
histological criosections using a specific anti-GFP antibody in conjunction with a 
second antibody recognizing mouse sarcomeric alpha actinin.  
According to the results obtained in vitro, we detected the appearance of GFP+ 
myocytes in all the treated animals. Notably, also in these experimental setting, 
the miRNAs significantly improved the number of recombination events, up to 
4-fold over untreated AAV-Control vector (P<0.01) (figure 21, panel C). 
Moreover, we confirmed the miRNAs overexpression by Real Time 
quantification using RNA samples deriving from a portion of unfixed treated 
hearts. Figure 21, panel D shows some representative fluorescence microscope 
images of myocardium from control and microRNAs treated mice; the increased 
number of GFP+ fibers in the hsa-miR-520c and hsa-miR-302d treated samples 
in comparison to control is evident. Quantification of the homologous 






Figure 21: (A) Representative images of hi-titer AAV9 particles production. (B) 
Experimental workflow. (C) Results deriving from the eGFP+ fiber contents in 
longitudinal heart sections of three miR-520c-3p and miR-302d-3p treated Cas9+ 
mice compared to the basal level of HR (Menke-van der Houven van Oordt, 
McGeoch et al.). (D) Representative images of heart sections of control mice and 
miRNAs treated animals. Data are mean ± SEM (N = 3 individual mice, 2 slides each); 








In the last decade, the discovery and optimization of the CRISPR/Cas9 
technology, firstly described as a sort of bacterial immune system (Ishino, 
Shinagawa et al. 1987) and then modified to become an eukaryote genome 
editing tool (Cong, Ran et al. 2013), has dramatically changed the perspectives 
of gene therapy. Among the plethora of possible applications, the chance to 
target and cleave with high precision specific sequences in the human genome 
has encouraged researchers to look at this technique as a possible way to 
achieve the precise correction of hereditary, disease-causing mutations.  
Thanks to the RNA-guided activity of Cas9, a double-stranded DNA break is 
created at the target site of the genomic DNA. Then, mammalian cells repair it, 
however, they preferentially employ the NHEJ DNA repair mechanism. 
Unfortunately, this is an error-prone mechanism active throughout the cell 
cycle, which might lead to either insertion or deletion of random nucleotides 
into the cleaved sequence. On the other hand, in mammalian cells, double-
stranded DNA breaks might be fixed with the HR-dependent mechanism as well. 
Homologous directed repair, in the presence of a suitable identical or similar 
template DNA, mediates the precise restoration of the damaged sequence; 
hence, it has always been considered as the gold standard for gene therapy of 
inherited mutations (Thomas and Capecchi 1987). Nevertheless, in mammals, 
HR is most active only in the G2/S phase of the cell cycle and almost turned off in 
post mitotic cells and tissues, such as cardiomyocytes and neurons. Despite 
Cas9 activity has strongly improved the possibility to insert, eliminate or modify 
peculiar sequences in the genome, this technology is still far from being used in 
therapeutic applications. Consequently, there is a strong need to find new 








4.1 A high-content robotized screening identified novel factors to improve 
CRISPR/Cas9-mediated homologous recombination 
This project has addressed the question how HR efficiency might be improved. 
We focused on the identification of innovative factors to specifically increase the 
Cas9-based HR activity and adapt this technology for cardiac gene therapy 
applications. Since HR relies on a very complex process, we decided to study the 
effect of endogenous, multi-target molecules, such as microRNAs using a 
robotized, unbiased high-throughput approach. For this purpose, we designed a 
triple-plasmids transfection assay that allowed us to recognize single HR events 
in a high-content format and to evaluate the single miRNAs effect. The HR 
reporter (pCUB-eGFP-Y66S) corresponds to an eGFP expression cassette 
bearing a single point mutation in lysine 201 (resulting in Tyr66 to Ser66 amino 
acid conversion), which leads to the formation of a misfolded and not 
fluorescent protein (Tran, Liu et al. 2003). The DNA template for correction is a 
promoterless and truncated WT eGFP sequence, also carrying a silent, single 
point mutation in the PAM recognition site, in order to avoid DNA cleavage once 
HR occurs (pGEM T easy_delta20GFP*). Lastly, the CRISPR/Cas9 system is 
provided by the third plasmid, which corresponds to the humanized sequence of 
the Streptococcus pyogenes Cas9 and the sgRNA, driving the cleavage specificity 
of the nuclease. We are well aware that this system is based on transient 
plasmid transfection and thus it monitors HR occurring on episomal DNA, 
therefore not necessarily reflecting the complexity of epigenetic modification of 
chromosomal targets. As an alternative, we considered the creation of a stable 
U2OS cell clone containing an integrated version of the template. However, we 
eventually preferred the transient approach for essentially two reasons. First, it 
avoids the problem of target site selection. Multiple evidences indicated that not 
all targets in the genome are equally accessible to Cas9 and, even less, to HR 
events. Operating from an episomal target avoids a bias due to the integration 
locus while it also maximizes the probability of recombination events, being 
both the target and the homologous template present in multiple copies after 




in light of adapting it to screenings in primary cells, such as cardiomyocytes, for 
which stable clones cannot be obtained while transfection using AAV6 vectors is 
feasible and efficient. 
For the screening, we arrayed in 384 well plates a series of 2,042 human 
microRNA mimics (miRBASe version 21.1) and we reverse transfected them in 
U2OS cells. The results of the screening confirmed our assumption that 
microRNAs, being pleiotropic modulators of virtually all biological functions, 
may also act as strong positive and negative regulators of HR. We ended up with 
a list of 20 molecules that significantly boosted HR frequency (up to 3-fold over 
control). Interestingly, 10 out of the top 20 miRNA hits belong to two enriched 
miRNA clusters: miR-520 and miR-302. These miRNAs share the same seed 
sequence (AAGUGC) and probably modulate the same gene targets and 
pathways. Moreover, many of them are known to be commonly expressed as 
clusters in embryonic and pluripotent stem cells, while turned off in fully 
differentiated tissues. Indeed, to identify the miRNAs profile of hESC lines and 
comparing it with primary human mesenchimal stem cells (hMSCs), Barroso-del 
Jesus and collaborators performed real time PCR quantification of 170 human 
miRNAs. The results of these experiments confirmed a significant expression of 
the miR302-367 cluster in hESC, which was barely detectable in hMSCs and 
normal adult tissues. According to the previous observation, in the publication of 
Ren and co-workers the miR-520 cluster was enriched in hESC in comparison to 
adult cells (Barroso-delJesus, Romero-Lopez et al. 2008, Ren, Jin et al. 2009). 
Importantly, the selected 20 miRNAs were effective at improving the efficiency 
of HR on a gene target present on an episomal plasmid, as in the case of our 
screening, but also on genes integrated into the host cell genome. Of note, 
when the relative efficiency of the selected miRNAs was compared after 
transfection into U2OS cells bearing the reporter eGFP_Y66S stably integrated 
into the AAVS-1 locus, the most effective molecule was hsa-miR-4469.  
Barely anything is known about this microRNA. The expression of miR-4469 was 
reported for the first time in malignant human B cells (Jima, Zhang et al. 2010) 




details were provided by a study from Cao and collaborators, in which these 
authors described the role of miR-4469 in increasing tumor metastasis motility 
by the direct inhibition of CDK3 (Cao, Xiao et al. 2017). The specific seed 
sequence of miR-4469 (CUCCCU) is completely different from the one 
characterizing the miR-520 and miR-302 clusters, implying that it probably 
regulates a different and distinct set of target genes. 
 
4.2 The effect of the selected microRNAs was HR-specific, without affecting 
NHEJ  
Considering the tendency of mammalian cells to choose NHEJ as the preferred 
repair mechanism to resolve double-stranded DNA breaks, we investigated 
whether the miRNAs identified from the screening only act specifically on HR. 
More specifically, we evaluated the effect of the top 20 selected molecules on 
NHEJ using a plasmid reporter designed for this purpose (Bennardo, Cheng et al. 
2008), again using an assay based on transient transfection. The results of this 
test confirmed that none of the hits belonging to the miR-520 or miR-302 
clusters were effective with this reporter, underlying their peculiar action on HR. 
Interestingly, in this experimental setting, only hsa-miR-143 was capable to also 
improve NHEJ. This microRNA was recently described as a potential tumor 
suppressor in several human cancers (Borralho, Kren et al. 2009, Noguchi, Yasui 
et al. 2013, Yan, Chen et al. 2014). Indeed, its expression was reported to 
increase p53 levels in the presence of DNA damage and to mediate MDM2 
downregulation, therefore playing a role in the DNA damage-induced cell death 
program (Zhang, Sun et al. 2013). Whether, and to what extent, these findings 
might be related to the effect of miR-143 on HR and NHEJ that we discovered in 
our study remains a matter for future investigation 
 
4.3 Effect of the selected microRNAs on cell proliferation 
To search for possible molecular mechanisms at the basis of the observed 
miRNAs effect, we first focused on the observation that HR occurs only in 




different phases of cell cycle (Cho, Campbell et al. 1998). Hence, we speculated 
on the possibility that our selected miRNAs might induce cell cycle alterations 
that could push cells in S or G2/M, when HR is maximally active (Aylon, Liefshitz 
et al. 2004). By an accurate analysis of the cell cycle profile of treated and 
untreated control U2OS cells, we indeed demonstrated that all the three 
miRNAs were able to increase the percentage of cells in S and G2/M phases 
(from 20% to almost 30%). This effect was more evident for hsa-miR-520c-3p 
and hsa-miR-302d-3p. It is of interest to remark that these two microRNA are 
known to be highly expressed in ES cells, as also discussed above. In these cells, 
HR is known to occur at very high frequency compared to other cell types (Tichy, 
Pillai et al. 2010). In addition, it is well established that these cells spend a 
significant proportion of their cell cycle time in G2/M (White and Dalton 2005). It 
is tempting to speculate that one or both of these occurrences might be due to 
the expression of these microRNAs. As a matter of fact, downregulation of 
members of the miR-302 family in ES cells stimulates differentiation of these 
cells (Parchem, Moore et al. 2015) and thus, presumably, also the reduction of 
the proportion of cells in G2/M. It will be interesting to analyze, therefore, 
whether blockage of miR-302 or miR-520 family members in hES cells also 
results in diminished rates of HR. 
Other reports in the literature link these two miRNAs with the control of cell 
proliferation also in other cell types. Li and collaborators have shown that hsa-
miR-520c was able to boost the proliferation and progression of gastric cancer 
by directly targeting IRF2 (Li, Wen et al. 2016). Xu and co-workers revealed that 
miR-302d activity promotes proliferation of pluripotent stem cell-derived 
cardiomyocytes by suppressing LATS2 (Xu, Yang et al. 2019). Work from our 
own laboratory on microRNAs stimulating the capacity of neonatal 
cardiomyocyte to proliferate revealed that the miR-302 and miR-520 families 
contain microRNAs that are powerful inducer of proliferation of these cells 
(Eulalio, Mano et al. 2012). In this respect, however, it is important to observe 
that there is no apparent correlation between the capacity of microRNA to 




the comparison of the screening reported in this Thesis and the results by Eulalio 
and collaborators. Hsa-miR-4469 itself (which was not present in the original 
screening for cardiomyocyte proliferation) is very effective at stimulating HR but 
ineffective in activating cardiomyocyte proliferation (data not shown).  
 
4.4 Effect of the selected microRNAs and the DNA damage response 
An issue that stemmed from the observation that the selected microRNAs 
perturb the normal cell cycle profile was to understand whether they might 
directly induce DNA damage and the activation of cell cycle checkpoints. 
To answer this question, we evaluated the activation and accumulation of CHK2 
and H2AX proteins. The first is a factor belonging to the DNA damage-spreading 
cascade, which is rapidly activated and phosphorylated by ATM in response to 
ionizing radiations mediating G2 phase arrest (Matsuoka, Rotman et al. 2000). 
The histone variant H2AX regulates one of the earliest steps in DSB recognition. 
Upon occurrence of a DSB, ATM phosphorylates the carboxyl-terminal of H2A 
present on the chromatin surrounding the damage site, (γ-H2AX); this 
corresponds to a mark for triggering the recruitment of many chromatin 
modifiers and DSB repair factors, allowing efficient DNA repair. (Downs, Allard 
et al. 2004, Morrison, Highland et al. 2004).  
Interestingly, in contrast to UV-treated control cells that served as a positive 
control, neither CHK2 nor H2AX was activated following the sole transfection of 
the selected microRNAs into the cells. 
On the other hand, we observed a significant accumulation of RAD51 and of the 
three MRN complex components (MRE11, NBN and RAD50) at the mRNA and 
protein levels in both hsa-miR-520c-3p and hsa-miR-302d-3p-treated samples. 
The MRN complex is known to mediate the early recognition of the broken ends 
at the DSB site (Zha, Boboila et al. 2009, Taylor, Cecillon et al. 2010). RAD51 
instead is a HR specific ATP-dependent recombinase, which forms a 
nucleoprotein filament on ssDNA in a gap or at the 3’ end of a DSB to prevent its 
degradation. It also creates a catalytic center that allows the invasion and 




these data clearly point to a direct modulation of factors belonging to the HR 
machinery by the overexpression of hsa-miR-302 and hsa-miR-520 microRNA 
clusters. However, this property is not shared by hsa-miR-4469.   
 
4.5 Mechanism of action of hsa-miR-4469  
Since miRNAs are multi-target, endogenous molecules that regulate hundreds 
of genes, we decided to analyze the transcriptome of miRNA-treated U2OS 
cells, to identify both direct and indirect targets. There was a strict correlation 
between the modifications induced by hsa-miR-502c-3p and hsa-miR-302d-3p, 
both in the upregulated and downregulated genes; on the contrary, hsa-miR-
4469-treated samples exhibited a different expression pattern. Among the 
upregulated genes, we confirmed the presence of the MRN complex 
components and RAD51 protein; in addition, we also pointed out new HR-
associated genes, such as MSH2 (a component of the BRCA-1-associated 
genome surveillance complex) (Wang, Cortez et al. 2000) and MDC1 (a nuclear 
protein known to interact with RAD51 during HR) (Zhang, Ma et al. 2005). 
Moreover, we confirmed the downregulation of G1-related cyclins and kinases. 
Interestingly, among the hsa-miR-4469 possible targets, there was MAPK11 
(p38β), which, together with the other MAPKs (ERK and JNK), is known to play a 
role in the HR-mediated DNA repair process (Golding, Rosenberg et al. 2007). 
Golding and coworkers described p38β inhibition as a positive stimulus for HR. 
This observation encouraged us to further study the correlation between 
MAPK11 inhibition and the effect of miR-4469 on HR enhancement.  
We indeed discovered that MAPK11 is a direct target of hsa-miR-4469. By Real 
Time PCR and western blot quantification, we observed a significant MAPK11 
inhibition at both the mRNA and protein levels in hsa-miR-4469-transfected 
cells. Moreover, TargetScan analysis revealed that a perfect match exists 
between the hsa-miR-4469 seed sequence and the 3’-UTR of the human 
MAPK11 mRNA. When we transfected HeLa cells with hsa-miR-4469 and a 




we observed a significant downregulation of luciferase activity, indicative of 
direct targeting of this sequence by the microRNA.  
As a further prove of the role of MAPK11 inhibition on HR modulation, the highly 
specific p38 chemical inhibitor SB203580 (Jarnicki, Conroy et al. 2008) was able 
to induce alone a 5-fold enrichment of GFP-positive cells in U2OS cells 
transfected with the triple plasmid HR reporter assay. The effect was additive in 
the presence of hsa-miR-4469 (up to 7-fold of HR over control). Interestingly, 
SB203580 is a well studied and described molecule already used as a potent 
inhibitor of the inflammatory response and cytokine production in vivo (Badger, 
Bradbeer et al. 1996, Herman, Krawczynska et al. 2014). A phase II study is now 
evaluating the effect of another MAPK11 chemical inhibitor, ARRY 797, to 
prevent the ventricular dilatation in patients affected by a Laminin A/C-related 
cardiomyopathy (https://clinicaltrials.gov/ct2/show/NCT03439514).  
Future experiments may focus on testing the effect of these chemicals on HR in 
vivo, by administering these drugs together with the heart-specific HR reporter 
system described in paragraph 3.10 and figure 20. 
 
4.6 Gene editing in cardiomyocytes  
Developing a precise, HR-mediated gene therapy method is a promising 
approach for the treatment of many monogenic and inherited disease-causing 
mutations, especially in terminally differentiated tissues, including the heart. 
Multiple indeed evidence indicates that precise gene targeting and repair 
through NHEJ is possible in cardiomyocytes ex vivo and in vivo in muscles, retina 
or heart using the CRISPR/Cas9 components delivered using AAV9 vectors 
(Bengtsson, Hall et al. 2017, Johansen, Molenaar et al. 2017, Yu, Mookherjee et 
al. 2017). However, it is known that HR-based DSB repair is a molecular process 
largely restricted to proliferating cells, which occurs mainly in the S and G2 
phases of the cell cycle. This process is believed to be almost turned off in post 
mitotic cells and tissues, such as adult cardiomyocytes. 
Given the properties of our microRNAs, we decided to investigate the possibility 




vivo upon the delivery of hsa-miR-520c, hsa-miR-302d and hsa-miR-4469. We 
used the same system described in the manuscript by Ishizu and collaborators, 
entailing the precise genomic insertion of a promoterless GFP cassette with a 
self-cleaving T2A peptide at its 5’ end, in frame with the cardio-specific myosin-
light chain 2 (Myl2) gene (Ishizu, Higo et al. 2017). 
Primary neonatal CMs deriving from mice expressing Cas9 exclusively in the 
heart (Carroll, Makarewich et al. 2016) were infected with a combination of two 
AAV6 vectors. One delivered the single guide RNA targeting an intron sequence 
at the end of the last exon of the Myl2 locus, while the other one introduced the 
template DNA for HR (the T2A-GFP cassette bracketed by two 800 bp 
homologous arms). In accordance with the Ishino et al. findings, also in our 
experimental settings we recognized the appearance of recombined cells, 
reaching, at the 1x104 m.o.i., 1% of HDR-mediated gene targeting in neonatal 
cardiomyocytes. Notably, by transfecting CMs with the selected synthetic 
miRNAs, we reached a 3-fold increase in HR positive events in hsa-miR-520c-3p- 
and hsa-miR-302d-3p-treated samples. Hsa-miR-4469 treatment was less 
effective at improving HR, inducing up to 2-fold more HR-mediated GFP 
insertions over control. This finding is important because it suggests that 
differentiated, although neonatal, cardiomyocytes are able to respond to the 
stimulus imposed by miRNAs treatment and can repair the Cas9-generated 
DSBs by HR. Moreover, our results highlight a conserved spectrum of regulation 
of the three human miRNAs in mouse cardiomyocytes. It is known that hsa-miR-
302d-3p is important for cardiomyocyte proliferation during development, when 
it is expressed at high levels, and is sufficient to induce cardiomyocyte 
proliferation and promote cardiac regeneration if re-expressed in the adult 
(Tian, Liu et al. 2015); moreover, its reactivation in the adult induced 
cardiomyocyte dedifferentiation. This may suggest that this also promotes the 
re-expression of the HR machinery protein complex.  
 




Considering our in vitro results showing the feasibility to stimulate homologous 
directed repair in differentiated, largely post-mitotic neonatal mice 
cardiomyocytes, we decided to investigate whether this process also might 
occur in neonatal mice in vivo.  
For these experiments, we produced AAV9 particles (known to efficiently and 
uniformly transduce the heart tissue in vivo) coding for the sgRNA, for hsa-miR-
302d and hsa-miR-520c, and containing the sequence of the template for HR. 
Unfortunately, although we obtained also a plasmid construct designed to 
express miR-4469, we failed to detect any RNA expression after transfecting it 
into U2OS cells. Thus, we did not proceed with hsa-miR-4469 AAV9 particle 
production and optimization experiments are still ongoing.  
We pre-treated Cas9+ mice at 1-day post birth by intraperitoneally injecting the 
AAV9 coding for the different miRNAs (1x1012 vgp/mouse) and using as control 
an empty AAV9-MCS vector. After 8 hours, we injected a mixture of equal 
amounts of vector genomes for each of the different AAV9 HR system 
components (6x1011 vgp/mouse).  
In these conditions, fluorescence microscope analysis of histological 
preparations from heart samples one month after treatment allowed the 
detection of a significant number of HR events (200 GFP+ fibers/section, 2 
sections for each heart were analyzed), in the form of GFP+ myocardial fibers. 
Furthermore, in these experiments we were also able to detect a significant 
increase in the number of HR events in hsa-miR-520c-3p- and hsa-miR-302d-3p-
treated animals (3-4 fold change over control mice infected with AAV9-MCS). 
From the same samples we also evaluated the levels of miRNAs overexpression, 















4.8 Conclusions and future perspectives 
To the best of our knowledge, the experimental work described in this Thesis is 
the first one that systematically analyzed the effect of all human miRNAs on HR. 
The identified, pro-recombinogenic miRNAs (hsa-miR-520c-3p, hsa-miR-302d-
3p and hsa-miR-4469) have never been previously associated with HR. 
Additional work is clearly needed to bring these results further. 
First, our understanding of the mechanism of action of the selected miRNAs is 
still scanty. The finding that all three miRNAs increase the time cells spend in 
G2/M is consistent with their pro-recombinogenic effect but the mechanism by 
which this occurs is still obscure. Consistent with this conclusion, it also remains 
unclear whether the finding that hsa-miR-520c-3p and hsa-miR-302d-3p 
increase the levels of pro-recombinogenic proteins is secondary to the G2/M 
increase or is a separate, direct effect of the microRNAs. In the latter case, the 
mechanism by which this is exerted needs to be understood.  
Second, the results obtained by delivering the miRNAs in neonatal hearts are 
very encouraging towards the development of a precise gene correction 
approach in vivo. However, we still miss data on the efficacy of the system in 
adult hearts. Neonatal cardiomyocytes are largely different from adult 
cardiomyocytes in terms of proliferative capacity, metabolism, cytoskeletal and 
centrosome organization, connections at the intercalated disk, and, finally, 
sarcomeric structure. To what extent these differences, in particular, their 
withdrawal from the cell cycle, can be overcome by any of the three selected 
microRNAs needs to be experimentally tested and understood. 
Third, the HDR process in mammalian cells unfavorably competes with the most 
frequent and error-prone NHEJ repair mechanism. We still do not understand 




inhibition of NHEJ, for example by transient RNA interference against the Ku 
proteins or DNA-PKcs, might boost the efficacy of the selected miRNAs is an 
interesting experiment that we plan to perform in the near future.  
Fourth, our experiments clearly indicate that the presence of the homologous 
template for recombination is not a limiting factor for the HR process to occur. 
This is most likely due to the very efficient AAV vector system, which could have 
stimulated HR repair. Moreover, AAV genomes by themselves are known to 
preferentially interact with the DNA damage response and HR protein 
machinery (Cervelli, Palacios et al. 2008). To what extent the selected miRNAs 
also directly affect AAV biology and might boost AAV transduction efficiency is 
another very interesting spin-off project consequent to our results.  
Fifth and final, it will also be important to understand what is the role of the 
chromatin status and architecture in proximity of the Cas9-induced DSB. From 
the paper of Mano and collaborators in our laboratory we already know that 
chromatin remodeling factors strongly influence AAV transduction (Mano, 
Ippodrino et al. 2015). Furthermore, other investigator have reported that a 
modification of histone dosage can modulate HR frequency (Liang, Burkhart et 
al. 2012). Starting by taking advantage of the transcriptome data we have 
generated, we wish to explore the possible alterations in chromatin modifiers 
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